<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:media="http://search.yahoo.com/mrss/" xmlns:podcast="https://podcastindex.org/namespace/1.0">
  <channel>
    <atom:link href="https://feeds.simplecast.com/K2gejSy4" rel="self" title="MP3 Audio" type="application/atom+xml"/>
    <atom:link href="https://simplecast.superfeedr.com" rel="hub" xmlns="http://www.w3.org/2005/Atom"/>
    <generator>https://simplecast.com</generator>
    <title>Decera Clinical Education Neuroscience Podcast</title>
    <description>Updates on new data and best practices in patient care across a wide variety of psychiatric and neurological illnesses from Decera Clinical Education. Gain a deeper understanding and practical clinical insights on topics ranging from bipolar depression to Parkinson’s disease psychosis. Select episodes available for CME/CE credit.</description>
    <copyright>2021 Decera Clinical Education Neuroscience Podcast</copyright>
    <language>en</language>
    <pubDate>Wed, 18 Mar 2026 19:55:03 +0000</pubDate>
    <lastBuildDate>Wed, 18 Mar 2026 19:55:13 +0000</lastBuildDate>
    <image>
      <link>https://neurologypodcast.simplecast.com</link>
      <title>Decera Clinical Education Neuroscience Podcast</title>
      <url>https://image.simplecastcdn.com/images/ec61b327-3a4f-4bed-a4d2-7c7d2df62891/e96b35c2-4ebb-4668-b5a2-1778f88c7009/3000x3000/decera-neu-podcast-show-icon.jpg?aid=rss_feed</url>
    </image>
    <link>https://neurologypodcast.simplecast.com</link>
    <itunes:type>episodic</itunes:type>
    <itunes:summary>Updates on new data and best practices in patient care across a wide variety of psychiatric and neurological illnesses from Decera Clinical Education. Gain a deeper understanding and practical clinical insights on topics ranging from bipolar depression to Parkinson’s disease psychosis. Select episodes available for CME/CE credit.</itunes:summary>
    <itunes:author>Decera Clinical Education</itunes:author>
    <itunes:explicit>false</itunes:explicit>
    <itunes:image href="https://image.simplecastcdn.com/images/ec61b327-3a4f-4bed-a4d2-7c7d2df62891/e96b35c2-4ebb-4668-b5a2-1778f88c7009/3000x3000/decera-neu-podcast-show-icon.jpg?aid=rss_feed"/>
    <itunes:new-feed-url>https://feeds.simplecast.com/K2gejSy4</itunes:new-feed-url>
    <itunes:keywords>movement disorders, neuromuscular disorders, mood disorders</itunes:keywords>
    <itunes:owner>
      <itunes:name>Decera Clinical Education</itunes:name>
      <itunes:email>support@deceraclinical.com</itunes:email>
    </itunes:owner>
    <itunes:category text="Education">
      <itunes:category text="Courses"/>
    </itunes:category>
    <itunes:category text="Science">
      <itunes:category text="Life Sciences"/>
    </itunes:category>
    <itunes:category text="Health &amp; Fitness">
      <itunes:category text="Medicine"/>
    </itunes:category>
    <item>
      <guid isPermaLink="false">59f95101-818c-405c-bbae-ee9c49e7ccc8</guid>
      <title>What’s Next in MS Care: Guidelines &amp; Pipeline</title>
      <description><![CDATA[<p>Multiple sclerosis care is evolving fast, from what current AAN guidance emphasizes to what’s emerging in the treatment pipeline. In this episode, Patricia K. Coyle, MD, FAAN, FANA, reviews practical, patient-centered principles for MS management, including shared decision-making, realistic expectations, adherence, monitoring, and optimizing comorbidities and lifestyle factors. She also explains when to reassess and potentially switch therapy based on relapses, disability progression, and MRI activity, and highlights pipeline advances such as CNS-penetrant BTK inhibitors and other investigational approaches.</p>
<p><strong>Presenters:</strong><br><strong>Patricia K. Coyle, MD, FAAN, FANA</strong><br>
 Distinguished Professor of Neurology<br>
 Vice Chair for Academic Affairs<br>
 Department of Neurology<br>
 Stony Brook Renaissance School of Medicine<br>
 Director, MS Comprehensive Care Center<br>
 Stony Brook, New York</p>
<p>Link to full program:<br><a href="https://bit.ly/4dhvLAL" target="_blank" rel="noopener noreferrer">https://bit.ly/4dhvLAL</a></p>
<p>Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 18 Mar 2026 19:55:03 +0000</pubDate>
      <author>support@deceraclinical.com (Patricia K. Coyle MD FAAN FANA)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/whats-next-in-ms-care-guidelines-pipeline-WOYXTSk3</link>
      <content:encoded><![CDATA[<p>Multiple sclerosis care is evolving fast, from what current AAN guidance emphasizes to what’s emerging in the treatment pipeline. In this episode, Patricia K. Coyle, MD, FAAN, FANA, reviews practical, patient-centered principles for MS management, including shared decision-making, realistic expectations, adherence, monitoring, and optimizing comorbidities and lifestyle factors. She also explains when to reassess and potentially switch therapy based on relapses, disability progression, and MRI activity, and highlights pipeline advances such as CNS-penetrant BTK inhibitors and other investigational approaches.</p>
<p><strong>Presenters:</strong><br><strong>Patricia K. Coyle, MD, FAAN, FANA</strong><br>
 Distinguished Professor of Neurology<br>
 Vice Chair for Academic Affairs<br>
 Department of Neurology<br>
 Stony Brook Renaissance School of Medicine<br>
 Director, MS Comprehensive Care Center<br>
 Stony Brook, New York</p>
<p>Link to full program:<br><a href="https://bit.ly/4dhvLAL" target="_blank" rel="noopener noreferrer">https://bit.ly/4dhvLAL</a></p>
<p>Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="21310158" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/7bb3143b-649e-454a-9769-302f33cbdfb6/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=7bb3143b-649e-454a-9769-302f33cbdfb6&amp;feed=K2gejSy4"/>
      <itunes:title>What’s Next in MS Care: Guidelines &amp; Pipeline</itunes:title>
      <itunes:author>Patricia K. Coyle MD FAAN FANA</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/829aaefb-535f-4489-af47-65017aadfa3d/3000x3000/101469_multiple_sclerosis_me_33000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:22:11</itunes:duration>
      <itunes:summary>Patricia K. Coyle, MD, FAAN, FANA, turns multiple sclerosis guidance into real-world decisions, from setting expectations and monitoring to knowing exactly when it’s time to switch. Dive inside the pipeline, including CNS-penetrant BTK inhibitors and other emerging therapies that could reshape progressive MS care.</itunes:summary>
      <itunes:subtitle>Patricia K. Coyle, MD, FAAN, FANA, turns multiple sclerosis guidance into real-world decisions, from setting expectations and monitoring to knowing exactly when it’s time to switch. Dive inside the pipeline, including CNS-penetrant BTK inhibitors and other emerging therapies that could reshape progressive MS care.</itunes:subtitle>
      <itunes:keywords>tolebrutinib, secondary progressive multiple sclerosis, fingolimod, john cunningham virus, remibrutinib, alt, surveillance mri, ppms, pml, fenebrutinib, primary progressive multiple sclerosis, jc virus, progressive multifocal leukoencephalopathy, neuroimmunology, ocrelizumab, shared decision making, natalizumab, orelabrutinib, alanine aminotransferase, microglia, frexalimab, aan, spms, cd40 ligand, progression independent of relapse activity, american academy of neurology, relapse prevention, pira, bruton tyrosine kinase inhibitors, evobrutinib, biib091, btki, ms guidelines</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>46</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">0c5fc321-74df-416c-9aa9-5aa2985049f1</guid>
      <title>Therapy Trends &amp; Tipping Points in MS: A Case-Based Look at High-Risk Disease and Emerging Treatments</title>
      <description><![CDATA[<p>Wondering what is coming next in MS care beyond today’s disease-modifying therapies? This episode spotlights CNS-penetrant oral BTK inhibitors and the fast-moving pipeline targeting neuroinflammation, immune reset, and future CNS repair, then brings it to life with a real patient case that tests treatment selection and the decision to switch therapy. Led by Patricia K. Coyle, MD, FAAN, FANA, it is a practical listen for healthcare professionals who want a clear sense of where MS treatment is heading and why it matters now.</p>
<p><strong>Presenters:</strong></p>
<p><strong>Patricia K. Coyle, MD, FAAN, FANA</strong><br>
 Distinguished Professor of Neurology<br>
 Vice Chair for Academic Affairs<br>
 Department of Neurology<br>
 Stony Brook Renaissance School of Medicine<br>
 Director, MS Comprehensive Care Center<br>
 Stony Brook, New York</p>
<p>Link to full program:<br><a href="https://bit.ly/4sau7px" target="_blank" rel="noopener noreferrer">https://bit.ly/4sau7px</a></p>
<p>Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Fri, 13 Mar 2026 13:26:29 +0000</pubDate>
      <author>support@deceraclinical.com (Patricia K. Coyle MD FAAN FANA)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/therapy-trends-tipping-points-in-ms-a-case-based-look-at-high-risk-disease-and-emerging-treatments-XCKHfTym</link>
      <content:encoded><![CDATA[<p>Wondering what is coming next in MS care beyond today’s disease-modifying therapies? This episode spotlights CNS-penetrant oral BTK inhibitors and the fast-moving pipeline targeting neuroinflammation, immune reset, and future CNS repair, then brings it to life with a real patient case that tests treatment selection and the decision to switch therapy. Led by Patricia K. Coyle, MD, FAAN, FANA, it is a practical listen for healthcare professionals who want a clear sense of where MS treatment is heading and why it matters now.</p>
<p><strong>Presenters:</strong></p>
<p><strong>Patricia K. Coyle, MD, FAAN, FANA</strong><br>
 Distinguished Professor of Neurology<br>
 Vice Chair for Academic Affairs<br>
 Department of Neurology<br>
 Stony Brook Renaissance School of Medicine<br>
 Director, MS Comprehensive Care Center<br>
 Stony Brook, New York</p>
<p>Link to full program:<br><a href="https://bit.ly/4sau7px" target="_blank" rel="noopener noreferrer">https://bit.ly/4sau7px</a></p>
<p>Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="16417109" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/08fe112e-2734-446e-a369-8a982aff730c/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=08fe112e-2734-446e-a369-8a982aff730c&amp;feed=K2gejSy4"/>
      <itunes:title>Therapy Trends &amp; Tipping Points in MS: A Case-Based Look at High-Risk Disease and Emerging Treatments</itunes:title>
      <itunes:author>Patricia K. Coyle MD FAAN FANA</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/3373bd91-d19f-499d-a511-bd3e1be66127/3000x3000/101469_multiple_sclerosis_me23000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:17:06</itunes:duration>
      <itunes:summary>Explore what’s next in multiple sclerosis (MS) care, spotlighting CNS-penetrant oral BTK inhibitors and a broader pipeline targeting neuroinflammation, immune reset, and future CNS repair. Also featured is a real patient case to highlight practical decisions around therapy selection and when to switch treatment, guided by Patricia K. Coyle, MD, FAAN, FANA.</itunes:summary>
      <itunes:subtitle>Explore what’s next in multiple sclerosis (MS) care, spotlighting CNS-penetrant oral BTK inhibitors and a broader pipeline targeting neuroinflammation, immune reset, and future CNS repair. Also featured is a real patient case to highlight practical decisions around therapy selection and when to switch treatment, guided by Patricia K. Coyle, MD, FAAN, FANA.</itunes:subtitle>
      <itunes:keywords>risk counseling, smoldering, immune reset, car t-cell, neuroinflammation, anti-cd3, antigen-specific tolerance, cd8, remyelination, foralumab, dmt, microglia, disease-modifying therapy, inverse vaccine, btk inhibitors, emerging multiple sclerosis therapies, progression independent of relapse activity, pira, ng-01, kappa free light chain, bruton tyrosine kinase inhibitors, dhodh, vidofludimus, autoreactome, cns penetrant</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>47</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">58025b86-316a-48a7-b08e-68e77a5004df</guid>
      <title>Smoldering and Spiking: Mapping MS and Modern DMTs</title>
      <description><![CDATA[<p>Multiple sclerosis (MS) is increasingly understood as a spectrum in which relapsing activity and progression can overlap, creating a need for smart, individualized use of disease-modifying therapies. Listen in to learn from Patricia K. Coyle, MD, FAAN, FANA, for a practical review of today’s MS DMT options, with a focus on high-efficacy monoclonal antibodies such as anti-CD20 therapies, how healthcare professionals think about progression concepts like PIRA and RAW, and what emerging trial designs like OCTOPUS may mean for improving treatment options in progressive MS.</p>
<p><strong>Presenter:</strong></p>
<p><strong>Patricia K. Coyle, MD, FAAN, FANA</strong><br>
 Distinguished Professor of Neurology<br>
 Vice Chair for Academic Affairs<br>
 Department of Neurology<br>
 Stony Brook Renaissance School of Medicine<br>
 Director, MS Comprehensive Care Center<br>
 Stony Brook, New York</p>
<p>Link to full program:<br><a href="https://bit.ly/3PdRks4" target="_blank" rel="noopener noreferrer">https://bit.ly/3PdRks4</a></p>
<p>Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 11 Mar 2026 20:01:25 +0000</pubDate>
      <author>support@deceraclinical.com (Patricia K. Coyle MD FAAN FANA)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/smoldering-and-spiking-mapping-ms-and-modern-dmts-_Nl9pIDi</link>
      <content:encoded><![CDATA[<p>Multiple sclerosis (MS) is increasingly understood as a spectrum in which relapsing activity and progression can overlap, creating a need for smart, individualized use of disease-modifying therapies. Listen in to learn from Patricia K. Coyle, MD, FAAN, FANA, for a practical review of today’s MS DMT options, with a focus on high-efficacy monoclonal antibodies such as anti-CD20 therapies, how healthcare professionals think about progression concepts like PIRA and RAW, and what emerging trial designs like OCTOPUS may mean for improving treatment options in progressive MS.</p>
<p><strong>Presenter:</strong></p>
<p><strong>Patricia K. Coyle, MD, FAAN, FANA</strong><br>
 Distinguished Professor of Neurology<br>
 Vice Chair for Academic Affairs<br>
 Department of Neurology<br>
 Stony Brook Renaissance School of Medicine<br>
 Director, MS Comprehensive Care Center<br>
 Stony Brook, New York</p>
<p>Link to full program:<br><a href="https://bit.ly/3PdRks4" target="_blank" rel="noopener noreferrer">https://bit.ly/3PdRks4</a></p>
<p>Get access to all of our new podcasts by subscribing to the Decera Clinical Education Neuroscience Podcast on Apple Podcasts, YouTube Music, or Spotify.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="18575033" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/2dcc853e-9e60-4784-9f68-1aba21d81835/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=2dcc853e-9e60-4784-9f68-1aba21d81835&amp;feed=K2gejSy4"/>
      <itunes:title>Smoldering and Spiking: Mapping MS and Modern DMTs</itunes:title>
      <itunes:author>Patricia K. Coyle MD FAAN FANA</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/24308934-4bd6-4e51-bc37-a5eeb8290556/3000x3000/101469_multiple_sclerosis_me13000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:19:20</itunes:duration>
      <itunes:summary>This episode delivers a practical update on multiple sclerosis (MS) treatment, explaining MS as a spectrum of relapsing attacks and smoldering, progression-related neurodegeneration (PIRA/RAW) and what that means for slowing disability. It reviews today’s multiple sclerosis disease-modifying therapies, especially high-efficacy anti-CD20 monoclonals, as well as emerging trial designs, such as OCTOPUS, aimed at improving options for progressive MS and future CNS repair.</itunes:summary>
      <itunes:subtitle>This episode delivers a practical update on multiple sclerosis (MS) treatment, explaining MS as a spectrum of relapsing attacks and smoldering, progression-related neurodegeneration (PIRA/RAW) and what that means for slowing disability. It reviews today’s multiple sclerosis disease-modifying therapies, especially high-efficacy anti-CD20 monoclonals, as well as emerging trial designs, such as OCTOPUS, aimed at improving options for progressive MS and future CNS repair.</itunes:subtitle>
      <itunes:keywords>s1p, octopus, secondary progressive ms, (mams), cladribine, raw, ofatumumab, anti-cd20, ublituximab, neurofilament light chain, gfap, ocrelizumab, natalizumab, progressive multiple sclerosis, relapsing multiple sclerosis, nfl, frexalimab, relapse-associated worsening, fumarate, progression independent of relapse activity, pira, multiple sclerosis disease-modifying therapies, smoldering inflammation, vidofludimus, teriflunomide, multi-arm multi-stage, primary progressive ms, alemtuzumab, neurodegeneration</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>45</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">feab5a11-c36d-4877-9036-f02eec21be38</guid>
      <title>Beyond the Podium: Continuing the Q&amp;A on Schizophrenia</title>
      <description><![CDATA[<p>In this podcast episode, Dr Jonathan Meyer answers additional questions from learners at our Psychopharmacology Update conference. Questions explore other disease states where psychosis can occur, practical considerations around special populations, tolerability, drug combinations, and the potential future of muscarinic-based therapies. For additional activities in this program including a ClinicalThought commentary, a CME/CE/CPE certified on-demand webcast and a downloadable slideset, go to: <a href="https://bit.ly/4qjcYcj" target="_blank">https://bit.ly/4qjcYcj</a></p><p><strong>Faculty</strong>:</p><p><strong>Jonathan M. Meyer, MD, DLFAPA</strong><br />Voluntary Clinical Professor of Psychiatry<br />University of California, San Diego<br />Senior Academic Adviser<br />California Department of State Hospitals<br />San Diego, California</p><p>Get access to all of our new podcasts by subscribing to the CCO Neuroscience Podcast on Apple Podcasts, YouTube Podcasts, or Spotify.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Mon, 12 Jan 2026 14:45:09 +0000</pubDate>
      <author>support@deceraclinical.com (Jonathan M. Meyer MD DLFAPA)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/beyond-the-podium-continuing-the-qa-on-schizophrenia-vajb1tyo-XdpyoG2N</link>
      <content:encoded><![CDATA[<p>In this podcast episode, Dr Jonathan Meyer answers additional questions from learners at our Psychopharmacology Update conference. Questions explore other disease states where psychosis can occur, practical considerations around special populations, tolerability, drug combinations, and the potential future of muscarinic-based therapies. For additional activities in this program including a ClinicalThought commentary, a CME/CE/CPE certified on-demand webcast and a downloadable slideset, go to: <a href="https://bit.ly/4qjcYcj" target="_blank">https://bit.ly/4qjcYcj</a></p><p><strong>Faculty</strong>:</p><p><strong>Jonathan M. Meyer, MD, DLFAPA</strong><br />Voluntary Clinical Professor of Psychiatry<br />University of California, San Diego<br />Senior Academic Adviser<br />California Department of State Hospitals<br />San Diego, California</p><p>Get access to all of our new podcasts by subscribing to the CCO Neuroscience Podcast on Apple Podcasts, YouTube Podcasts, or Spotify.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="34264395" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/619bfb38-83ad-4a28-b6a8-7ef45a037cb5/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=619bfb38-83ad-4a28-b6a8-7ef45a037cb5&amp;feed=K2gejSy4"/>
      <itunes:title>Beyond the Podium: Continuing the Q&amp;A on Schizophrenia</itunes:title>
      <itunes:author>Jonathan M. Meyer MD DLFAPA</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/46fda8df-195a-4c11-b1e1-568cbd6f511a/3000x3000/101149-schizophrenia-psychopharm-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:35:41</itunes:duration>
      <itunes:summary>In this podcast episode, Dr Jonathan Meyer answers additional questions from learners at our Psychopharmacology Update conference. Questions explore other disease states where psychosis can occur, practical considerations around special populations, tolerability, drug combinations, and the potential future of muscarinic-based therapies. </itunes:summary>
      <itunes:subtitle>In this podcast episode, Dr Jonathan Meyer answers additional questions from learners at our Psychopharmacology Update conference. Questions explore other disease states where psychosis can occur, practical considerations around special populations, tolerability, drug combinations, and the potential future of muscarinic-based therapies. </itunes:subtitle>
      <itunes:keywords>dopamine blockade, cognitive symptoms, clozapine, schizophrenia, muscarinic acetylcholine receptors, negative symptoms., trospium, psychosis, xanomeline, muscarinic agonists, augmentation, antipsychotics</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>44</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">ec4b853d-b2e3-4c19-bb3f-a42293926120</guid>
      <title>Cognitive Conversations: Key Findings on Alzheimer’s Disease Presented at CTAD</title>
      <description><![CDATA[<p>In this episode of “Cognitive Conversations,” expert faculty discuss breaking data presentations from the 2026 Clinical Trials on Alzheimer’s Disease conference held in San Diego, California, from December 1-4, 2025, and their implications for clinical practice.</p><p>Topics covered include:</p><ul><li>Evoke and evoke+ phase III trials of semaglutide</li><li>Subcutaneous lecanemab as initiation and maintenance treatment</li><li>Blood-based biomarker assays</li><li>Trontinemab and other brain shuttles</li><li>Tau targeting therapies in development</li><li>Preventive impact of BCG and herpes zoster vaccination</li></ul><p>This podcast episode is part of the CME/CE-accredited program, “Early Clues, Lasting Impact: Detecting and Treating Alzheimer’s Disease in Its Earliest Stages,” supported by an educational grant from Novo Nordisk. </p><p><strong>Faculty</strong>:</p><p><strong>Anton P. Porsteinsson, MD </strong><br />William B. and Sheila Konar Professor of Psychiatry, Neurology, and Neuroscience, and Medicine<br />Director, Alzheimer's Disease Care, Research and Education Program (AD-CARE)<br />University of Rochester School of Medicine and Dentistry<br />Rochester, New York</p><p><strong>Vijay K. Ramanan, MD, PhD</strong><br />Consultant and Associate Professor<br />Director, Alzheimer’s Disease Treatment Clinic<br />Department of Neurology<br />Mayo Clinic<br />Rochester, Minnesota </p><p>Link to obtain CME/CE credit: <br /><a href="https://bit.ly/4999otE" target="_blank">https://bit.ly/4999otE</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 23 Dec 2025 15:34:55 +0000</pubDate>
      <author>support@deceraclinical.com (Vijay K. Ramanan MD PhD, Anton P. Porsteinsson MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/cognitive-conversations-key-findings-on-alzheimers-disease-presented-at-ctad-NGJB8_Br</link>
      <content:encoded><![CDATA[<p>In this episode of “Cognitive Conversations,” expert faculty discuss breaking data presentations from the 2026 Clinical Trials on Alzheimer’s Disease conference held in San Diego, California, from December 1-4, 2025, and their implications for clinical practice.</p><p>Topics covered include:</p><ul><li>Evoke and evoke+ phase III trials of semaglutide</li><li>Subcutaneous lecanemab as initiation and maintenance treatment</li><li>Blood-based biomarker assays</li><li>Trontinemab and other brain shuttles</li><li>Tau targeting therapies in development</li><li>Preventive impact of BCG and herpes zoster vaccination</li></ul><p>This podcast episode is part of the CME/CE-accredited program, “Early Clues, Lasting Impact: Detecting and Treating Alzheimer’s Disease in Its Earliest Stages,” supported by an educational grant from Novo Nordisk. </p><p><strong>Faculty</strong>:</p><p><strong>Anton P. Porsteinsson, MD </strong><br />William B. and Sheila Konar Professor of Psychiatry, Neurology, and Neuroscience, and Medicine<br />Director, Alzheimer's Disease Care, Research and Education Program (AD-CARE)<br />University of Rochester School of Medicine and Dentistry<br />Rochester, New York</p><p><strong>Vijay K. Ramanan, MD, PhD</strong><br />Consultant and Associate Professor<br />Director, Alzheimer’s Disease Treatment Clinic<br />Department of Neurology<br />Mayo Clinic<br />Rochester, Minnesota </p><p>Link to obtain CME/CE credit: <br /><a href="https://bit.ly/4999otE" target="_blank">https://bit.ly/4999otE</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="36956908" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/0de6466a-b94b-43f0-a762-d76680a83a37/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=0de6466a-b94b-43f0-a762-d76680a83a37&amp;feed=K2gejSy4"/>
      <itunes:title>Cognitive Conversations: Key Findings on Alzheimer’s Disease Presented at CTAD</itunes:title>
      <itunes:author>Vijay K. Ramanan MD PhD, Anton P. Porsteinsson MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/8e7e1709-1733-4200-a05a-4c04adfb2d25/3000x3000/101678-ad-ctc-rt-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:38:29</itunes:duration>
      <itunes:summary>In this podcast episode, Alzheimer’s disease experts Anton P. Porsteinsson, MD, and Vijay K. Ramanan, MD, PhD, discuss the most recent results presented at CTAD about AD treatments currently available as well as in development.</itunes:summary>
      <itunes:subtitle>In this podcast episode, Alzheimer’s disease experts Anton P. Porsteinsson, MD, and Vijay K. Ramanan, MD, PhD, discuss the most recent results presented at CTAD about AD treatments currently available as well as in development.</itunes:subtitle>
      <itunes:keywords>alzheimer’s treatment news, pet scan vs blood biomarkers, aging and memory research, alzheimer’s disease podcast, subcutaneous lecanemab fda approval, bcg and shingles vaccine dementia research., ad at ctad podcast, anti-amyloid antibodies, alzheimer’s disease prevention vaccines, alzheimer’s biomarkers, brain health podcast, dementia clinical updates, clinical trials on alzheimer&apos;s disease, tau-targeting therapies in alzheimer’s, expert alzheimer’s roundtable, clinical trials podcast, novo nordisk semaglutide trial, ad, trontinemab, blood-based alzheimer’s diagnostics, ptau217 blood tests, alzheimer’s drug pipeline, microtubule binging region tau antibodies, glp-1, ctad 2025 alzheimer’s update, alzheimer’s therapy pipeline, apoe4 alzheimer’s risk factors, latest alzheimer’s research, semaglutide, neurology cme podcast, brain shuttle technology, brain shuttle antibody therapy, mtbr, alzheimer&apos;s disease, evoke and evoke plus studies, tau antibodies, ctad, vaccine impact on dementia prevention, ad biomarkers, subcutaneous lecanemab, apoe4, neurologist discussions alzheimer’s, glp-1 and cognition, plasma biomarkers</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>42</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">45d38d51-f061-47ba-99fb-31cf28b7b448</guid>
      <title>Seize Control: Real-world Strategies for Personalized Rescue and Epilepsy Care</title>
      <description><![CDATA[<p>In this podcast episode, epilepsy specialists Danielle Becker, MD, MS, FAES, and Sarah Weatherspoon, MD, discuss the personalization of the most recently available epilepsy rescue treatments for younger kids and their implementation by the patient care team.</p><p><strong>Faculty:</strong></p><p><strong>Danielle Becker, MD, MS, FAES </strong><br />Division Director of Epilepsy<br />Associate Professor of Neurology<br />The Ohio State University Wexner Medical Center<br />Columbus, Ohio </p><p><strong>Sarah Weatherspoon, MD</strong><br />Associate Chief of Child Neurology<br />Tuberous Sclerosis Center of Excellence, Neurology Co-Director<br />Le Bonheur Children's Hospital<br />University of Tennessee Health Science Center<br />Memphis, Tennessee</p><p>Resources mentioned in this episode:</p><ul><li><a href="https://www.epilepsy.com/living-epilepsy/toolbox/seizure-action-plans" target="_blank">Epilepsy Foundation Seizure Action Plan Toolkit</a></li><li><a href="https://www.cdc.gov/epilepsy/mew-network/index.html" target="_blank">CDC Managing Epilepsy Well (MEW) Network</a></li></ul><p>Link to Brain Health Hub with additional educational activities: <br /><a href="https://bit.ly/3Y12Isx" target="_blank">https://bit.ly/3Y12Isx</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Thu, 18 Dec 2025 18:12:51 +0000</pubDate>
      <author>support@deceraclinical.com (Danielle Becker MD MS FAES, Sarah Weatherspoon MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/seize-control-real-world-strategies-for-personalized-rescue-and-epilepsy-care-OIg17JD_</link>
      <content:encoded><![CDATA[<p>In this podcast episode, epilepsy specialists Danielle Becker, MD, MS, FAES, and Sarah Weatherspoon, MD, discuss the personalization of the most recently available epilepsy rescue treatments for younger kids and their implementation by the patient care team.</p><p><strong>Faculty:</strong></p><p><strong>Danielle Becker, MD, MS, FAES </strong><br />Division Director of Epilepsy<br />Associate Professor of Neurology<br />The Ohio State University Wexner Medical Center<br />Columbus, Ohio </p><p><strong>Sarah Weatherspoon, MD</strong><br />Associate Chief of Child Neurology<br />Tuberous Sclerosis Center of Excellence, Neurology Co-Director<br />Le Bonheur Children's Hospital<br />University of Tennessee Health Science Center<br />Memphis, Tennessee</p><p>Resources mentioned in this episode:</p><ul><li><a href="https://www.epilepsy.com/living-epilepsy/toolbox/seizure-action-plans" target="_blank">Epilepsy Foundation Seizure Action Plan Toolkit</a></li><li><a href="https://www.cdc.gov/epilepsy/mew-network/index.html" target="_blank">CDC Managing Epilepsy Well (MEW) Network</a></li></ul><p>Link to Brain Health Hub with additional educational activities: <br /><a href="https://bit.ly/3Y12Isx" target="_blank">https://bit.ly/3Y12Isx</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="34152794" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/2c538401-9a34-4526-aad7-7cc782ff647d/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=2c538401-9a34-4526-aad7-7cc782ff647d&amp;feed=K2gejSy4"/>
      <itunes:title>Seize Control: Real-world Strategies for Personalized Rescue and Epilepsy Care</itunes:title>
      <itunes:author>Danielle Becker MD MS FAES, Sarah Weatherspoon MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/25039748-9f36-4cb3-b781-ffb9c440536a/3000x3000/101663-epilepsy-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:35:34</itunes:duration>
      <itunes:summary>In this podcast episode, epilepsy specialists Danielle Becker, MD, MS, FAES, and Sarah Weatherspoon, MD, discuss the personalization of the most recently available epilepsy rescue treatments for young and older patients and their implementation by the patient care team.</itunes:summary>
      <itunes:subtitle>In this podcast episode, epilepsy specialists Danielle Becker, MD, MS, FAES, and Sarah Weatherspoon, MD, discuss the personalization of the most recently available epilepsy rescue treatments for young and older patients and their implementation by the patient care team.</itunes:subtitle>
      <itunes:keywords>epilepsy, sudep, pediatric epilepsy, seizure, epilepsy emergency care, sudden unexpected death in epilepsy, cluster seizures, nasal benzodiazepines, seizure control, tuberous sclerosis., rescue therapies for seizures, intranasal midazolam, status epilepticus, adult epilepsy, rectal benzodiazepines, transition of care in epilepsy, rectal diazepam, intranasal diazepam, seizure action plan</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>41</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">634c8125-ba46-4b90-a4eb-39074d6910a9</guid>
      <title>Cognitive Conversations: Brain Health in Neurology</title>
      <description><![CDATA[<p>In this episode, Alireza Atri, MD, PhD, discusses his approach to patient conversations on brain health and provides advice to healthcare professionals practicing in community neurology settings, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.</p><p><strong>Faculty:</strong></p><p><strong>Alireza Atri, MD, PhD </strong><br />Chief Medical Officer, Banner Research<br />Phoenix, Tucson and Sun City, Arizona<br />Director, Banner Sun Health Research Institute<br />Sun City, Arizona</p><p><strong>Robin Martinez</strong><br />Patient Advocate<br />Coordinator of Online Communities<br />Website Administration<br />Smart Patients Inc.<br />Denver, Colorado</p><p>Resources mentioned in this episode:</p><ul><li>Alzheimer’s Association: DETeCD-ADRD Clinical Practice Guidelines for Specialty Care <br /><a href="https://bit.ly/4kqtYt5" target="_blank">https://bit.ly/4kqtYt5</a></li><li>American Geriatrics Society: 2023 Beers Criteria for Potentially Inappropriate Medication Use in Older Adults <br /><a href="https://bit.ly/44zN8qG" target="_blank">https://bit.ly/44zN8qG</a></li><li>MoCA (Montreal Cognitive Assessment) : [Link to: https://mocacognition.com/]</li></ul><p>Link to obtain CME/CE credit: <br /><a href="https://bit.ly/44khuP5" target="_blank">https://bit.ly/44khuP5</a></p><p>Link to Brain Health Hub with additional educational activities:<br /><a href="https://bit.ly/4kziu6T" target="_blank">https://bit.ly/4kziu6T</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 23 Jul 2025 13:35:17 +0000</pubDate>
      <author>support@deceraclinical.com (Alireza Atri MD PhD, Robin Martinez)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/brain-health-podcast-neurology-RJK21uCl</link>
      <content:encoded><![CDATA[<p>In this episode, Alireza Atri, MD, PhD, discusses his approach to patient conversations on brain health and provides advice to healthcare professionals practicing in community neurology settings, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.</p><p><strong>Faculty:</strong></p><p><strong>Alireza Atri, MD, PhD </strong><br />Chief Medical Officer, Banner Research<br />Phoenix, Tucson and Sun City, Arizona<br />Director, Banner Sun Health Research Institute<br />Sun City, Arizona</p><p><strong>Robin Martinez</strong><br />Patient Advocate<br />Coordinator of Online Communities<br />Website Administration<br />Smart Patients Inc.<br />Denver, Colorado</p><p>Resources mentioned in this episode:</p><ul><li>Alzheimer’s Association: DETeCD-ADRD Clinical Practice Guidelines for Specialty Care <br /><a href="https://bit.ly/4kqtYt5" target="_blank">https://bit.ly/4kqtYt5</a></li><li>American Geriatrics Society: 2023 Beers Criteria for Potentially Inappropriate Medication Use in Older Adults <br /><a href="https://bit.ly/44zN8qG" target="_blank">https://bit.ly/44zN8qG</a></li><li>MoCA (Montreal Cognitive Assessment) : [Link to: https://mocacognition.com/]</li></ul><p>Link to obtain CME/CE credit: <br /><a href="https://bit.ly/44khuP5" target="_blank">https://bit.ly/44khuP5</a></p><p>Link to Brain Health Hub with additional educational activities:<br /><a href="https://bit.ly/4kziu6T" target="_blank">https://bit.ly/4kziu6T</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="19841030" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/b68b302e-0c57-4084-89b2-e3db748174ee/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=b68b302e-0c57-4084-89b2-e3db748174ee&amp;feed=K2gejSy4"/>
      <itunes:title>Cognitive Conversations: Brain Health in Neurology</itunes:title>
      <itunes:author>Alireza Atri MD PhD, Robin Martinez</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/fc945b57-5b23-4949-8bab-b286fd441163/3000x3000/100814-brain-health-ll-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:20:40</itunes:duration>
      <itunes:summary>In this podcast episode, a patient advocate from Smart Patients interviews dementia expert Alireza Atri, MD, PhD, on the optimization of brain health for patients in general neurology clinical settings.</itunes:summary>
      <itunes:subtitle>In this podcast episode, a patient advocate from Smart Patients interviews dementia expert Alireza Atri, MD, PhD, on the optimization of brain health for patients in general neurology clinical settings.</itunes:subtitle>
      <itunes:keywords>smart patients, aging, prevention, ad, alzheimer’s disease, mild cognitive decline, mci, dementia, brain health, memory</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>40</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">c10e088c-0568-4f91-9eb4-83cd8a775261</guid>
      <title>Cognitive Conversations: Brain Health in Psychiatry</title>
      <description><![CDATA[<table><tbody><tr><td><p>In this episode, dementia expert Anton Porsteinsson, MD, discusses his approach to conversations on brain health with patients and provides guidance for HCPs practicing in community psychiatry settings, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.</p><p><strong>Faculty:</strong></p><p><strong>Anton P. Porsteinsson, MD </strong><br />William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine<br />Director, Alzheimer’s Disease Care, Research and Education Program (AD-CARE)<br />University of Rochester School of Medicine and Dentistry<br />Rochester, New York</p><p><strong>Robin Martinez</strong><br />Patient Advocate<br />Coordinator of Online Communities<br />Website Administration<br />Smart Patients Inc.<br />Denver, Colorado</p><p>Resources mentioned in this episode:</p><ul><li>Mini Mental State Examination (MMSE) [Link to: https://www.psychdb.com/_media/mmse.]</li><li>Mini-Cog (quick dementia screening test) [Link to: https://mini-cog.com/]</li><li>MoCA (Montreal Cognitive Assessment) : [Link to: https://mocacognition.com/]</li><li>Alzheimer’s Association Local Chapters [Link to:https://www.alz.org/chapter-search]</li><li>Local Department of Aging [Link to : https://www.thecountyoffice.com/department-of-aging/]</li></ul><p>Link to obtain CME/CE credit: <br /><a href="https://bit.ly/3IAbyc7" target="_blank">https://bit.ly/3IAbyc7</a></p><p>Link to Brain Health Hub with additional educational activities: <br /><a href="https://bit.ly/40Jgth4" target="_blank">https://bit.ly/40Jgth4</a></p><p> </p></td></tr></tbody></table><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 9 Jul 2025 12:51:20 +0000</pubDate>
      <author>support@deceraclinical.com (Anton P. Porsteinsson MD, Robin Martinez)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/brain-health-podcast-psychiatry-_IZtbUJ0</link>
      <content:encoded><![CDATA[<table><tbody><tr><td><p>In this episode, dementia expert Anton Porsteinsson, MD, discusses his approach to conversations on brain health with patients and provides guidance for HCPs practicing in community psychiatry settings, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.</p><p><strong>Faculty:</strong></p><p><strong>Anton P. Porsteinsson, MD </strong><br />William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine<br />Director, Alzheimer’s Disease Care, Research and Education Program (AD-CARE)<br />University of Rochester School of Medicine and Dentistry<br />Rochester, New York</p><p><strong>Robin Martinez</strong><br />Patient Advocate<br />Coordinator of Online Communities<br />Website Administration<br />Smart Patients Inc.<br />Denver, Colorado</p><p>Resources mentioned in this episode:</p><ul><li>Mini Mental State Examination (MMSE) [Link to: https://www.psychdb.com/_media/mmse.]</li><li>Mini-Cog (quick dementia screening test) [Link to: https://mini-cog.com/]</li><li>MoCA (Montreal Cognitive Assessment) : [Link to: https://mocacognition.com/]</li><li>Alzheimer’s Association Local Chapters [Link to:https://www.alz.org/chapter-search]</li><li>Local Department of Aging [Link to : https://www.thecountyoffice.com/department-of-aging/]</li></ul><p>Link to obtain CME/CE credit: <br /><a href="https://bit.ly/3IAbyc7" target="_blank">https://bit.ly/3IAbyc7</a></p><p>Link to Brain Health Hub with additional educational activities: <br /><a href="https://bit.ly/40Jgth4" target="_blank">https://bit.ly/40Jgth4</a></p><p> </p></td></tr></tbody></table><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="27085517" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/b7cbeff7-09df-41a6-8f4f-6b80bdacdaa7/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=b7cbeff7-09df-41a6-8f4f-6b80bdacdaa7&amp;feed=K2gejSy4"/>
      <itunes:title>Cognitive Conversations: Brain Health in Psychiatry</itunes:title>
      <itunes:author>Anton P. Porsteinsson MD, Robin Martinez</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/6c79a8a6-bbcc-48e6-b46c-7e79b3b57305/3000x3000/100814-brain-health-pod4-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:28:12</itunes:duration>
      <itunes:summary>In this podcast episode, a patient advocate from Smart Patients interviews dementia expert Anton P. Porsteinsson, MD, on the optimization of brain health in psychiatric practice.</itunes:summary>
      <itunes:subtitle>In this podcast episode, a patient advocate from Smart Patients interviews dementia expert Anton P. Porsteinsson, MD, on the optimization of brain health in psychiatric practice.</itunes:subtitle>
      <itunes:keywords>smart patients, aging, prevention, ad, alzheimer’s disease, mild cognitive decline, mci, dementia, brain health, memory</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>39</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">246ea197-3ebe-48b2-be84-adf8290e1c84</guid>
      <title>Cognitive Conversations: Brain Health in Obstetrics and Gynecology</title>
      <description><![CDATA[<p>In this episode, Genevieve Neal-Perry, MD, PhD, discusses her approach to conversations on brain health with her patients in obstetrics and gynecology settings, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.</p><p><strong>Faculty:</strong></p><p><strong>Genevieve Neal-Perry, MD, PhD </strong><br />Robert A. Ross Distinguished Professor<br />Chair of Obstetrics and Gynecology<br />University of North Carolina School of Medicine<br />Chapel Hill, North Carolina</p><p><strong>Robin Martinez</strong><br />Patient Advocate<br />Coordinator of Online Communities<br />Website Administration<br />Smart Patients Inc.<br />Denver, Colorado</p><p>Resources mentioned in this episode:</p><ul><li>Smart Patients, an online community for patients and their families [Link to: https://www.smartpatients.com/]</li></ul><p>Link to obtain CME/CE credit: <br /><a href="https://bit.ly/4lH4BEt" target="_blank">https://bit.ly/4lH4BEt</a></p><p>Link to Brain Health Hub with additional educational activities:<br /><a href="https://bit.ly/4nJrgSG" target="_blank">https://bit.ly/4nJrgSG</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 8 Jul 2025 19:45:08 +0000</pubDate>
      <author>support@deceraclinical.com (Genevieve Neal-Perry MD PhD, Robin Martinez)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/brain-health-podcast-ob-gyn-CiXPm1YB</link>
      <content:encoded><![CDATA[<p>In this episode, Genevieve Neal-Perry, MD, PhD, discusses her approach to conversations on brain health with her patients in obstetrics and gynecology settings, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.</p><p><strong>Faculty:</strong></p><p><strong>Genevieve Neal-Perry, MD, PhD </strong><br />Robert A. Ross Distinguished Professor<br />Chair of Obstetrics and Gynecology<br />University of North Carolina School of Medicine<br />Chapel Hill, North Carolina</p><p><strong>Robin Martinez</strong><br />Patient Advocate<br />Coordinator of Online Communities<br />Website Administration<br />Smart Patients Inc.<br />Denver, Colorado</p><p>Resources mentioned in this episode:</p><ul><li>Smart Patients, an online community for patients and their families [Link to: https://www.smartpatients.com/]</li></ul><p>Link to obtain CME/CE credit: <br /><a href="https://bit.ly/4lH4BEt" target="_blank">https://bit.ly/4lH4BEt</a></p><p>Link to Brain Health Hub with additional educational activities:<br /><a href="https://bit.ly/4nJrgSG" target="_blank">https://bit.ly/4nJrgSG</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="24981510" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/cc823adb-285e-4e97-8c28-4d1e08562c63/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=cc823adb-285e-4e97-8c28-4d1e08562c63&amp;feed=K2gejSy4"/>
      <itunes:title>Cognitive Conversations: Brain Health in Obstetrics and Gynecology</itunes:title>
      <itunes:author>Genevieve Neal-Perry MD PhD, Robin Martinez</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/b6174c1e-1758-4e6e-b14c-e4c4a12d25ce/3000x3000/100814-brain-health-pod3-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:26:01</itunes:duration>
      <itunes:summary>In this podcast episode, a patient advocate from Smart Patients interviews Genevieve Neal-Perry, MD, PhD, an expert in reproductive endocrinology, on the optimization of brain health in obstetrics and gynecology settings.</itunes:summary>
      <itunes:subtitle>In this podcast episode, a patient advocate from Smart Patients interviews Genevieve Neal-Perry, MD, PhD, an expert in reproductive endocrinology, on the optimization of brain health in obstetrics and gynecology settings.</itunes:subtitle>
      <itunes:keywords>smart patients, aging, prevention, ad, brain fog, alzheimer’s disease, mild cognitive decline, mci, perimenopause, dementia, brain health, memory, menopause</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>38</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">542597cf-8478-46b8-ba00-9cc3f0af5fe1</guid>
      <title>Cognitive Conversations: Brain Health in Primary Care</title>
      <description><![CDATA[<p>In this episode, Pierre N. Tariot, MD, discusses his approach to conversations on brain health with his patients and their family members in primary care settings, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.</p><p><strong>Faculty:</strong><br />Pierre N. Tariot, MD<br />Director<br />Banner Alzheimer's Institute<br />Research Professor of Psychiatry<br />University of Arizona College of Medicine<br />Phoenix, Arizona</p><p>Robin Martinez<br />Patient Advocate<br />Coordinator of Online Communities<br />Website Administration<br />Smart Patients Inc.<br />Denver, Colorado</p><p>Resources mentioned in this episode:</p><ul><li><a href="https://www.bannerhealth.com/services/alzheimers/treatment-and-care/memory-care-centers/banner-alzheimers-institute" target="_blank">Banner Alzheimer Institute</a></li><li><a href="https://www.ahrq.gov/patient-safety/settings/multiple/project-echo/index.html" target="_blank">ECHO (Extension for Community Healthcare Outcomes)</a></li><li><a href="https://mocacognition.com/" target="_blank">MoCA (Montreal Cognitive Assessment)</a></li><li><a href="https://mini-cog.com/" target="_blank">Mini-Cog (quick dementia screening test)</a></li><li><a href="https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease" target="_blank">FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease</a></li><li><a href="https://www.thelancet.com/commissions-do/dementia-prevention-intervention-and-care" target="_blank">Lancet Commission: Dementia Prevention, Intervention, and Care 2024</a></li></ul><p>Link to obtain CME/CE credit:<br /><a href="https://bit.ly/4kk1vFs" target="_blank">https://bit.ly/4kk1vFs</a></p><p>Link to Brain Health Hub with additional educational activities:<br /><a href="https://bit.ly/3H4hoSl" target="_blank">https://bit.ly/3H4hoSl</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 8 Jul 2025 04:00:00 +0000</pubDate>
      <author>support@deceraclinical.com (Pierre N. Tariot MD, Robin Martinez)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/brain-health-podcast-primary-care-IWuXGU9N</link>
      <content:encoded><![CDATA[<p>In this episode, Pierre N. Tariot, MD, discusses his approach to conversations on brain health with his patients and their family members in primary care settings, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.</p><p><strong>Faculty:</strong><br />Pierre N. Tariot, MD<br />Director<br />Banner Alzheimer's Institute<br />Research Professor of Psychiatry<br />University of Arizona College of Medicine<br />Phoenix, Arizona</p><p>Robin Martinez<br />Patient Advocate<br />Coordinator of Online Communities<br />Website Administration<br />Smart Patients Inc.<br />Denver, Colorado</p><p>Resources mentioned in this episode:</p><ul><li><a href="https://www.bannerhealth.com/services/alzheimers/treatment-and-care/memory-care-centers/banner-alzheimers-institute" target="_blank">Banner Alzheimer Institute</a></li><li><a href="https://www.ahrq.gov/patient-safety/settings/multiple/project-echo/index.html" target="_blank">ECHO (Extension for Community Healthcare Outcomes)</a></li><li><a href="https://mocacognition.com/" target="_blank">MoCA (Montreal Cognitive Assessment)</a></li><li><a href="https://mini-cog.com/" target="_blank">Mini-Cog (quick dementia screening test)</a></li><li><a href="https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease" target="_blank">FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease</a></li><li><a href="https://www.thelancet.com/commissions-do/dementia-prevention-intervention-and-care" target="_blank">Lancet Commission: Dementia Prevention, Intervention, and Care 2024</a></li></ul><p>Link to obtain CME/CE credit:<br /><a href="https://bit.ly/4kk1vFs" target="_blank">https://bit.ly/4kk1vFs</a></p><p>Link to Brain Health Hub with additional educational activities:<br /><a href="https://bit.ly/3H4hoSl" target="_blank">https://bit.ly/3H4hoSl</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="25217657" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/2d35122e-522e-4f4f-ae83-0d63dcac41f4/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=2d35122e-522e-4f4f-ae83-0d63dcac41f4&amp;feed=K2gejSy4"/>
      <itunes:title>Cognitive Conversations: Brain Health in Primary Care</itunes:title>
      <itunes:author>Pierre N. Tariot MD, Robin Martinez</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/a9440a2b-eeb2-46b1-8689-78cd1ef7699f/3000x3000/100814-brain-health-pod2-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:26:16</itunes:duration>
      <itunes:summary>In this podcast episode, a patient advocate from Smart Patients interviews dementia expert Pierre N. Tariot, MD, on optimization of brain health for patients in primary care.</itunes:summary>
      <itunes:subtitle>In this podcast episode, a patient advocate from Smart Patients interviews dementia expert Pierre N. Tariot, MD, on optimization of brain health for patients in primary care.</itunes:subtitle>
      <itunes:keywords>smart patients, aging, prevention, ad, alzheimer’s disease, mild cognitive decline, mci, dementia, brain health, memory</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>37</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">b93eb0d9-c95e-48c8-8d39-9ef49957c957</guid>
      <title>Cognitive Conversations: Brain Health in Geriatric Practice</title>
      <description><![CDATA[<p>In this episode, Susan Scanland, MSN, CRNP, GNP-BC, CDP, discusses her approach to conversations on brain health with her patients and their family members in clinical practice as a gerontological nurse practitioner, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.</p><p>Faculty:</p><ul><li>Susan Scanland, MSN, CRNP, GNP-BC, CDP<br />CEO & Founder<br />Dementia Connection LLC<br />Clarks Summit, Pennsylvania</li><li>Robin Martinez<br />Patient Advocate<br />Coordinator of Online Communities<br />Website Administration<br />Smart Patients Inc.<br />Denver, Colorado</li></ul><p>Resources mentioned in this episode:</p><ul><li><a href="https://www.alz.org/getmedia/ef8f48f9-ad36-48ea-87f9-b74034635c1e/alzheimers-facts-and-figures.pdf" target="_blank">Alzheimer’s Association: 2025 Alzheimer’s Disease Facts and Figures</a></li><li><a href="https://www.thelancet.com/commissions-do/dementia-prevention-intervention-and-care" target="_blank">Lancet Commission: Dementia Prevention, Intervention, and Care 2024</a></li><li><a href="https://doi.org/10.1111/jgs.18372" target="_blank">American Geriatrics Society: 2023 Beers Criteria for Potentially Inappropriate Medication Use in Older Adults</a></li><li><a href="https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14333" target="_blank">Alzheimer’s Association: DETeCD-ADRD Clinical Practice Guidelines for Primary Care</a></li><li><a href="https://clinicaloptions.com/activities/neurology/brain-health-2025-resource/86404/info" target="_blank">Clinical Care Options: Integrating Brain Health Discussions Into Your Daily Routine</a></li></ul><p>Link to obtain CME/CE credit:<br /><a href="https://bit.ly/4mqHoaS" target="_blank">https://bit.ly/4mqHoaS</a></p><p>Link to Brain Health Hub with additional educational activities:<br /><a href="https://bit.ly/3H4hoSl" target="_blank">https://bit.ly/3H4hoSl</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 21 May 2025 04:00:00 +0000</pubDate>
      <author>support@deceraclinical.com (Susan Scanland MSN CRNP GNP-BC CDP, Robin Martinez)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/brain-health-podcast-geriatrics-end8jGym</link>
      <content:encoded><![CDATA[<p>In this episode, Susan Scanland, MSN, CRNP, GNP-BC, CDP, discusses her approach to conversations on brain health with her patients and their family members in clinical practice as a gerontological nurse practitioner, in a dialogue with Robin Martinez, a patient advocate from the Smart Patients online community. Supported by an educational grant from Lilly.</p><p>Faculty:</p><ul><li>Susan Scanland, MSN, CRNP, GNP-BC, CDP<br />CEO & Founder<br />Dementia Connection LLC<br />Clarks Summit, Pennsylvania</li><li>Robin Martinez<br />Patient Advocate<br />Coordinator of Online Communities<br />Website Administration<br />Smart Patients Inc.<br />Denver, Colorado</li></ul><p>Resources mentioned in this episode:</p><ul><li><a href="https://www.alz.org/getmedia/ef8f48f9-ad36-48ea-87f9-b74034635c1e/alzheimers-facts-and-figures.pdf" target="_blank">Alzheimer’s Association: 2025 Alzheimer’s Disease Facts and Figures</a></li><li><a href="https://www.thelancet.com/commissions-do/dementia-prevention-intervention-and-care" target="_blank">Lancet Commission: Dementia Prevention, Intervention, and Care 2024</a></li><li><a href="https://doi.org/10.1111/jgs.18372" target="_blank">American Geriatrics Society: 2023 Beers Criteria for Potentially Inappropriate Medication Use in Older Adults</a></li><li><a href="https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14333" target="_blank">Alzheimer’s Association: DETeCD-ADRD Clinical Practice Guidelines for Primary Care</a></li><li><a href="https://clinicaloptions.com/activities/neurology/brain-health-2025-resource/86404/info" target="_blank">Clinical Care Options: Integrating Brain Health Discussions Into Your Daily Routine</a></li></ul><p>Link to obtain CME/CE credit:<br /><a href="https://bit.ly/4mqHoaS" target="_blank">https://bit.ly/4mqHoaS</a></p><p>Link to Brain Health Hub with additional educational activities:<br /><a href="https://bit.ly/3H4hoSl" target="_blank">https://bit.ly/3H4hoSl</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="19820836" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/d2ae4b09-53c5-4403-b36d-9e3f66aeefd4/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=d2ae4b09-53c5-4403-b36d-9e3f66aeefd4&amp;feed=K2gejSy4"/>
      <itunes:title>Cognitive Conversations: Brain Health in Geriatric Practice</itunes:title>
      <itunes:author>Susan Scanland MSN CRNP GNP-BC CDP, Robin Martinez</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/a7c0c86b-7f2e-4c17-97b7-c0056c65d4fc/3000x3000/100814-brain-health-ll-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:20:33</itunes:duration>
      <itunes:summary>In this podcast episode, a patient advocate from Smart Patients interviews dementia expert Susan Scanland, MSN, CRNP, GNP-BC, CDP, on optimization of brain health for patients in geriatric clinical practice.</itunes:summary>
      <itunes:subtitle>In this podcast episode, a patient advocate from Smart Patients interviews dementia expert Susan Scanland, MSN, CRNP, GNP-BC, CDP, on optimization of brain health for patients in geriatric clinical practice.</itunes:subtitle>
      <itunes:keywords>smart patients, aging, prevention, ad, alzheimer’s disease, mild cognitive decline, mci, dementia, brain health, memory</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>36</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">8ec84ca3-9927-4a3a-be4f-8c89ffb71209</guid>
      <title>Inpatient Treatment of Severe COVID-19 in Patients Who Are Immunocompromisedn People Who Are Immunocompromised</title>
      <description><![CDATA[<p>Listen in as Cristina Mussini, MD; Martin Witzenrath, MD, FERS; and Michele Bartoletti, MD, PhD, discuss best practices in managing people who are immunocompromised with COVID-19 in the hospital setting, including: </p><ul><li>COVID-19 burden among this population</li><li>Initial workup to assess disease severity</li><li>Summary of COVID-19 guideline recommendations</li><li>A detailed patient case to illustrate key takeaways</li></ul><p><strong>Presenters</strong>:</p><p><strong>Michele Bartoletti, MD, PhD​</strong><br />Associate Professor of Infectious Diseases<br />Department of Biomedical Sciences<br />Humanitas University<br />Pieve Emanuele (MI), Italy<br />Head of Infectious Diseases Unit<br />IRCCS Humanitas Research Hospital<br />Rozzano (MI), Italy</p><p><strong>Cristina Mussini, MD​</strong><br />Full Professor of Infectious Diseases<br />Chief of the Department of Infectious Diseases<br />University of Modena and Reggio Emilia<br />Modena, Italy</p><p><strong>Martin Witzenrath, MD, FERS</strong><br />Medical Director<br />Charite Centrum 12<br />Internal Medicine & Dermatology<br />Professor and Chair for Respiratory Medicine and Critical Care<br />Department of Infectious Disease, Respiratory Medicine and Critical Care<br />Charite Campus Mitte/Campus Virchow Klinikum/Campus Benamin Franklin<br />Charite – University of Berlin<br />Berlin, Germany</p><p>Link to full program:<br /><a href="https://bit.ly/4fs7Hcb" target="_blank">https://bit.ly/4fs7Hcb</a></p><p>Downloadable slides: <br /><a href="https://bit.ly/4imCRU5" target="_blank">https://bit.ly/4imCRU5</a></p><p>Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Mon, 3 Mar 2025 20:17:27 +0000</pubDate>
      <author>support@deceraclinical.com (Michele Bartoletti MD PhD, Cristina Mussini MD, Martin Witzenrath MD FERS)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/covid-rounds-eu-episode-3-xvnCXwik</link>
      <content:encoded><![CDATA[<p>Listen in as Cristina Mussini, MD; Martin Witzenrath, MD, FERS; and Michele Bartoletti, MD, PhD, discuss best practices in managing people who are immunocompromised with COVID-19 in the hospital setting, including: </p><ul><li>COVID-19 burden among this population</li><li>Initial workup to assess disease severity</li><li>Summary of COVID-19 guideline recommendations</li><li>A detailed patient case to illustrate key takeaways</li></ul><p><strong>Presenters</strong>:</p><p><strong>Michele Bartoletti, MD, PhD​</strong><br />Associate Professor of Infectious Diseases<br />Department of Biomedical Sciences<br />Humanitas University<br />Pieve Emanuele (MI), Italy<br />Head of Infectious Diseases Unit<br />IRCCS Humanitas Research Hospital<br />Rozzano (MI), Italy</p><p><strong>Cristina Mussini, MD​</strong><br />Full Professor of Infectious Diseases<br />Chief of the Department of Infectious Diseases<br />University of Modena and Reggio Emilia<br />Modena, Italy</p><p><strong>Martin Witzenrath, MD, FERS</strong><br />Medical Director<br />Charite Centrum 12<br />Internal Medicine & Dermatology<br />Professor and Chair for Respiratory Medicine and Critical Care<br />Department of Infectious Disease, Respiratory Medicine and Critical Care<br />Charite Campus Mitte/Campus Virchow Klinikum/Campus Benamin Franklin<br />Charite – University of Berlin<br />Berlin, Germany</p><p>Link to full program:<br /><a href="https://bit.ly/4fs7Hcb" target="_blank">https://bit.ly/4fs7Hcb</a></p><p>Downloadable slides: <br /><a href="https://bit.ly/4imCRU5" target="_blank">https://bit.ly/4imCRU5</a></p><p>Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="14588339" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/53b2cd33-f546-4cab-9f4b-75c98e4f0136/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=53b2cd33-f546-4cab-9f4b-75c98e4f0136&amp;feed=K2gejSy4"/>
      <itunes:title>Inpatient Treatment of Severe COVID-19 in Patients Who Are Immunocompromisedn People Who Are Immunocompromised</itunes:title>
      <itunes:author>Michele Bartoletti MD PhD, Cristina Mussini MD, Martin Witzenrath MD FERS</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/a561221a-c831-49fb-bf50-1ad1dc5d59f5/3000x3000/100477-euro-track-rndtble-02-podcast-01-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:15:02</itunes:duration>
      <itunes:summary>Listen in as expert faculty discuss the burden of COVID-19 among people who are immunocompromised, how to assess illness severity in this population, and strategies to provide guideline-concordant care in the hospital setting.</itunes:summary>
      <itunes:subtitle>Listen in as expert faculty discuss the burden of COVID-19 among people who are immunocompromised, how to assess illness severity in this population, and strategies to provide guideline-concordant care in the hospital setting.</itunes:subtitle>
      <itunes:keywords>recommendation, immune-competent, immune-incompetent, world health organization, nih, inpatient, infectious diseases society of america, idsa, work up, infectious disease, covid-19, best practice, id, covid, who, sars-cov-2, national institutes of health, guideline, immunocompromised</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>35</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">39d6a6fa-ef78-4aec-a27d-ac5bfd59b290</guid>
      <title>Reaching Patients Where They Are: Experience With LAI Antipsychotics in Community Practice</title>
      <description><![CDATA[<p>In this episode, Dr Robert Cotes and Dr David Goldsmith discuss their clinical experience with long-acting injectable antipsychotic treatments in the Grady Health System, with a focus on communication strategies to educate patients on their treatment options and engage them in shared decision-making.</p><p><strong>Presenters</strong>: </p><p><strong>Robert O. Cotes, MD, DFAPA</strong><br />Associate Professor and Distinguished Physician<br />Director, Clinical & Research Program for Psychosis at Grady Health System<br />Director, Project ARROW at Grady Health System<br />Department of Psychiatry and Behavioral Sciences<br />Emory University School of Medicine<br />Atlanta, Georgia</p><p><strong>David R. Goldsmith, MD, MSc</strong><br />Associate Professor<br />Director, Inflammation, Motivation, and Negative Symptoms of Schizophrenia (InMotioNSS) Lab<br />Co-Director, Clinical & Research Program for Psychosis at Grady Health System<br />Director, PSTAR Clinic at Grady Memorial Hospital<br />Faculty, Emory Behavioral Immunology Program<br />Co-Director, Psychiatry Residency Research Track<br />Department of Psychiatry and Behavioral Sciences<br />Emory University School of Medicine<br />Atlanta, Georgia</p><p>This content is part of an online CME program supported by educational grants from Indivior Inc.; Otsuka America Pharmaceutical, Inc. and Lundbeck; and Teva Pharmaceuticals. </p><p>Link to full program: <a href="https://bit.ly/414XkY4" target="_blank">https://bit.ly/414XkY4</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 27 Nov 2024 19:59:15 +0000</pubDate>
      <author>support@deceraclinical.com (David R. Goldsmith MD MSc, Robert O. Cotes MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/2024-lai-podcast-j_X9PsFo</link>
      <content:encoded><![CDATA[<p>In this episode, Dr Robert Cotes and Dr David Goldsmith discuss their clinical experience with long-acting injectable antipsychotic treatments in the Grady Health System, with a focus on communication strategies to educate patients on their treatment options and engage them in shared decision-making.</p><p><strong>Presenters</strong>: </p><p><strong>Robert O. Cotes, MD, DFAPA</strong><br />Associate Professor and Distinguished Physician<br />Director, Clinical & Research Program for Psychosis at Grady Health System<br />Director, Project ARROW at Grady Health System<br />Department of Psychiatry and Behavioral Sciences<br />Emory University School of Medicine<br />Atlanta, Georgia</p><p><strong>David R. Goldsmith, MD, MSc</strong><br />Associate Professor<br />Director, Inflammation, Motivation, and Negative Symptoms of Schizophrenia (InMotioNSS) Lab<br />Co-Director, Clinical & Research Program for Psychosis at Grady Health System<br />Director, PSTAR Clinic at Grady Memorial Hospital<br />Faculty, Emory Behavioral Immunology Program<br />Co-Director, Psychiatry Residency Research Track<br />Department of Psychiatry and Behavioral Sciences<br />Emory University School of Medicine<br />Atlanta, Georgia</p><p>This content is part of an online CME program supported by educational grants from Indivior Inc.; Otsuka America Pharmaceutical, Inc. and Lundbeck; and Teva Pharmaceuticals. </p><p>Link to full program: <a href="https://bit.ly/414XkY4" target="_blank">https://bit.ly/414XkY4</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="31040748" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/a4216986-a45d-4b38-9d62-0920b38f8814/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=a4216986-a45d-4b38-9d62-0920b38f8814&amp;feed=K2gejSy4"/>
      <itunes:title>Reaching Patients Where They Are: Experience With LAI Antipsychotics in Community Practice</itunes:title>
      <itunes:author>David R. Goldsmith MD MSc, Robert O. Cotes MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/c52434e0-cdd2-4c97-b4e1-526a9e0f7fa9/3000x3000/7638-lai-me-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:32:10</itunes:duration>
      <itunes:summary>Dr Robert Cotes and Dr David Goldsmith, Codirectors of the Clinical and Research Program for Psychosis at Grady, part of the Emory University School of Medicine in Atlanta, discuss their clinical experience with long-acting injectable antipsychotic treatments, with a focus on communication strategies to educate patients on their treatment options and engage them in shared decision-making.</itunes:summary>
      <itunes:subtitle>Dr Robert Cotes and Dr David Goldsmith, Codirectors of the Clinical and Research Program for Psychosis at Grady, part of the Emory University School of Medicine in Atlanta, discuss their clinical experience with long-acting injectable antipsychotic treatments, with a focus on communication strategies to educate patients on their treatment options and engage them in shared decision-making.</itunes:subtitle>
      <itunes:keywords>sustenna, hafyera, schizophrenia, risperdal, aripiprazole, bipolar disorder, antipsychotic, long-acting antipsychotic, aristada, risperidone, olanzapine, psychosis, mania, abilify, invega, uzedy, perseris, lai, trinza, paliperidone</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>34</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">0db954f3-ab7d-46ef-9459-b5dc506d67da</guid>
      <title>What’s New in the Treatment of Rett Syndrome?</title>
      <description><![CDATA[<p>In this episode, David N. Lieberman, MD, PhD, and Eric Marsh, MD, PhD, discuss recent updates relevant to the treatment of Rett syndrome, including:</p><ul><li>The recently updated Comprehensive Care Guidelines from the International Rett Syndrome Foundation, available at rettsyndrome.org</li><li>Ongoing collection and analysis of longitudinal data within the Rett Syndrome Natural History Study</li><li>Efficacy and safety data from the double-blind, placebo-controlled phase III registrational LAVENDER trial evaluating oral trofinetide, a small molecule analogue of insulin-like growth factor 1</li><li>Topline results from phase III AVATAR and EXCELLENCE trials of the sigma-1 receptor agonist blarcamesine</li><li>Several early ongoing gene therapy trials</li></ul><p>Dr Lieberman and Dr Marsh complement this informative update with wisdom from their own clinical experience to provide a full picture of current treatment and management options available to patients with Rett syndrome.</p><p>Presenters: </p><p>David N. Lieberman, MD, PhD<br />Director, Comprehensive Rett Syndrome Clinic<br />Department of Neurology<br />Boston Children's Hospital<br />Boston, Massachusetts</p><p>Eric Marsh, MD PhD<br />Clinical Director, Orphan Disease Center<br />Director (MPI), CHOP/Penn IDDRC<br />Professor, Departments of Neurology and Pediatrics<br />Division of Neurology<br />Children’s Hospital of Philadelphia<br />Perelman School of Medicine<br />University of Pennsylvania<br />Philadelphia, Pennsylvania</p><p>This content is part of an online CME program in partnership with the International Rett Syndrome Foundation and supported by an educational grant from Acadia Pharmaceuticals. Link to full program:<br /><a href="https://bit.ly/4fJRRL0" target="_blank">https://bit.ly/4fJRRL0</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 14 Aug 2024 21:35:00 +0000</pubDate>
      <author>support@deceraclinical.com (David N. Lieberman MD PhD, Eric Marsh MD PhD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/2024-rett-podcast-CS2mIiBC</link>
      <content:encoded><![CDATA[<p>In this episode, David N. Lieberman, MD, PhD, and Eric Marsh, MD, PhD, discuss recent updates relevant to the treatment of Rett syndrome, including:</p><ul><li>The recently updated Comprehensive Care Guidelines from the International Rett Syndrome Foundation, available at rettsyndrome.org</li><li>Ongoing collection and analysis of longitudinal data within the Rett Syndrome Natural History Study</li><li>Efficacy and safety data from the double-blind, placebo-controlled phase III registrational LAVENDER trial evaluating oral trofinetide, a small molecule analogue of insulin-like growth factor 1</li><li>Topline results from phase III AVATAR and EXCELLENCE trials of the sigma-1 receptor agonist blarcamesine</li><li>Several early ongoing gene therapy trials</li></ul><p>Dr Lieberman and Dr Marsh complement this informative update with wisdom from their own clinical experience to provide a full picture of current treatment and management options available to patients with Rett syndrome.</p><p>Presenters: </p><p>David N. Lieberman, MD, PhD<br />Director, Comprehensive Rett Syndrome Clinic<br />Department of Neurology<br />Boston Children's Hospital<br />Boston, Massachusetts</p><p>Eric Marsh, MD PhD<br />Clinical Director, Orphan Disease Center<br />Director (MPI), CHOP/Penn IDDRC<br />Professor, Departments of Neurology and Pediatrics<br />Division of Neurology<br />Children’s Hospital of Philadelphia<br />Perelman School of Medicine<br />University of Pennsylvania<br />Philadelphia, Pennsylvania</p><p>This content is part of an online CME program in partnership with the International Rett Syndrome Foundation and supported by an educational grant from Acadia Pharmaceuticals. Link to full program:<br /><a href="https://bit.ly/4fJRRL0" target="_blank">https://bit.ly/4fJRRL0</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="32918926" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/4ae54869-dadf-417f-8e8f-5c3c12bfb3bb/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=4ae54869-dadf-417f-8e8f-5c3c12bfb3bb&amp;feed=K2gejSy4"/>
      <itunes:title>What’s New in the Treatment of Rett Syndrome?</itunes:title>
      <itunes:author>David N. Lieberman MD PhD, Eric Marsh MD PhD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/62c5b18f-3da1-493c-8e0f-51cb2a5c5558/3000x3000/7500-rett-me-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:34:17</itunes:duration>
      <itunes:summary>Listen to this podcast episode for a 2024 update on approved and investigational treatment for patients with Rett syndrome from 2 experts in pediatric neurology.</itunes:summary>
      <itunes:subtitle>Listen to this podcast episode for a 2024 update on approved and investigational treatment for patients with Rett syndrome from 2 experts in pediatric neurology.</itunes:subtitle>
      <itunes:keywords>gene therapy, trofinetide, genetic disorders, mecp2, complex care, developmental disorders, rett syndrome, neurology, blarcamesine</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>33</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">2eca115a-a710-4f06-aefa-3b76159d13e6</guid>
      <title>Assess the Efficacy and Safety of Emerging Strategies That Impact Brain Cholesterol Turnover</title>
      <description><![CDATA[<p>Link to CME: Claim Credit - <a href="https://bit.ly/3OByCaE" target="_blank">https://bit.ly/3OByCaE</a></p><p>In this episode, Drs. Halford and Hahn discuss the current treatment landscape of developmental and epileptic encephalopathies (DEEs), such as Lennox-Gastaut syndrome and Dravet syndrome, and the emerging role of brain cholesterol in addressing seizure frequency. The full episode covers:</p><ul><li>How to diagnose these epilepsies and the FDA-approved treatment options in the first-line and second-line settings</li><li>The role of antiseizure medications in DEE treatment management</li><li>The nonpharmacological treatment options available to patients with DEEs</li><li>The emerging role of brain cholesterol in neurologic diseases like DEEs and Alzheimer’s disease</li><li>Results from the ELEKTRA clinical trial, including cholesterol synthase inhibitors’ impact on seizure frequency</li><li>The future of soticlestat as a treatment option for pediatric patients with DEEs</li></ul><p>Presenters:</p><p><strong>Jonathan J. Halford, MD</strong><br />Professor<br />Director, Translational Research Unit<br />Department of Neurology<br />Medical University of South Carolina<br />Charleston, SC</p><p><strong>Cecil Hahn, MD, MPH, FRCPC</strong><br />Professor<br />Pediatric Epileptologist<br />University of Toronto<br />Toronto, Ontario, Canada</p><p>Content based on an online CME program supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.</p><p>Link to full program: <br /><a href="https://bit.ly/45UUpQy" target="_blank">https://bit.ly/45UUpQy</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Fri, 3 Nov 2023 18:36:47 +0000</pubDate>
      <author>support@deceraclinical.com (Jonathan J. Halford MD, Cecil Hahn MD MPH FRCPC)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/brain-cholesterol-in-dee-treatment-wpdixFnD</link>
      <content:encoded><![CDATA[<p>Link to CME: Claim Credit - <a href="https://bit.ly/3OByCaE" target="_blank">https://bit.ly/3OByCaE</a></p><p>In this episode, Drs. Halford and Hahn discuss the current treatment landscape of developmental and epileptic encephalopathies (DEEs), such as Lennox-Gastaut syndrome and Dravet syndrome, and the emerging role of brain cholesterol in addressing seizure frequency. The full episode covers:</p><ul><li>How to diagnose these epilepsies and the FDA-approved treatment options in the first-line and second-line settings</li><li>The role of antiseizure medications in DEE treatment management</li><li>The nonpharmacological treatment options available to patients with DEEs</li><li>The emerging role of brain cholesterol in neurologic diseases like DEEs and Alzheimer’s disease</li><li>Results from the ELEKTRA clinical trial, including cholesterol synthase inhibitors’ impact on seizure frequency</li><li>The future of soticlestat as a treatment option for pediatric patients with DEEs</li></ul><p>Presenters:</p><p><strong>Jonathan J. Halford, MD</strong><br />Professor<br />Director, Translational Research Unit<br />Department of Neurology<br />Medical University of South Carolina<br />Charleston, SC</p><p><strong>Cecil Hahn, MD, MPH, FRCPC</strong><br />Professor<br />Pediatric Epileptologist<br />University of Toronto<br />Toronto, Ontario, Canada</p><p>Content based on an online CME program supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.</p><p>Link to full program: <br /><a href="https://bit.ly/45UUpQy" target="_blank">https://bit.ly/45UUpQy</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="22276391" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/e3c35b43-3192-42c6-b6db-10910641f8b0/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=e3c35b43-3192-42c6-b6db-10910641f8b0&amp;feed=K2gejSy4"/>
      <itunes:title>Assess the Efficacy and Safety of Emerging Strategies That Impact Brain Cholesterol Turnover</itunes:title>
      <itunes:author>Jonathan J. Halford MD, Cecil Hahn MD MPH FRCPC</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/8a3ad371-13a4-4f85-ba83-9c5a8d27ace7/3000x3000/epilepsy-am-prp6760-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:23:03</itunes:duration>
      <itunes:summary>Expert faculty discuss the treatment landscape of pediatric patients with developmental and epileptic encephalopathies, such as Lennox-Gastaut syndrome and Dravet syndrome, and the emerging role of brain cholesterol in addressing seizure frequency as shown in the ELEKTRA clinical trial of soticlestat.</itunes:summary>
      <itunes:subtitle>Expert faculty discuss the treatment landscape of pediatric patients with developmental and epileptic encephalopathies, such as Lennox-Gastaut syndrome and Dravet syndrome, and the emerging role of brain cholesterol in addressing seizure frequency as shown in the ELEKTRA clinical trial of soticlestat.</itunes:subtitle>
      <itunes:keywords>developmental and epileptic encephalopathies, epilepsy, soticlestat, seizures, cecil hahn, pediatrics, ds, dravet syndrome, lgs, psychiatry, neurology, jonathan j. halford, brian cholesterol, dees, lennox-gastaut syndrome, elektra</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>32</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">6346702d-4605-4e97-a180-eca85608b230</guid>
      <title>Brain Cholesterol: The New Landscape of Neurological Disease Management</title>
      <description><![CDATA[<p>Link to CME: Claim Credit - <a href="https://bit.ly/3wbVkA1" target="_blank">https://bit.ly/3wbVkA1</a></p><p>In this episode, Drs. Halford and White discuss the emerging role of brain cholesterol in the development and potential treatment of neurological diseases like epilepsy or Alzheimer and Huntington diseases. The full episode covers:</p><ul><li>Overview of brain cholesterol and its function in the body</li><li>Pathogenesis potential for certain diseases via brain cholesterol</li><li>Emerging research on a cholesterol synthase inhibitor as a novel therapy</li><li>The future of soticlestat as a potential treatment option for pediatric epilepsies—Lennox-Gastaut syndrome and Dravet syndrome—and other neurological diseases</li></ul><p><strong>Presenters</strong>:</p><p><strong>Jonathan J. Halford, MD</strong><br />Professor<br />Director, Translational Research Unit<br />Department of Neurology<br />Medical University of South Carolina<br />Charleston, SC</p><p><strong>H. Steve White, PhD</strong><br />Professor, Department of Pharmacy<br />Co-Director, Center for Epilepsy Drug Discovery<br />School of Pharmacy<br />University of Washington<br />Seattle, Washington</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 1 Nov 2023 13:35:33 +0000</pubDate>
      <author>support@deceraclinical.com (Jonathan J. Halford MD, H. Steven White PhD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/brain-cholesterol-in-neurological-disease-management-NqSghSnS</link>
      <content:encoded><![CDATA[<p>Link to CME: Claim Credit - <a href="https://bit.ly/3wbVkA1" target="_blank">https://bit.ly/3wbVkA1</a></p><p>In this episode, Drs. Halford and White discuss the emerging role of brain cholesterol in the development and potential treatment of neurological diseases like epilepsy or Alzheimer and Huntington diseases. The full episode covers:</p><ul><li>Overview of brain cholesterol and its function in the body</li><li>Pathogenesis potential for certain diseases via brain cholesterol</li><li>Emerging research on a cholesterol synthase inhibitor as a novel therapy</li><li>The future of soticlestat as a potential treatment option for pediatric epilepsies—Lennox-Gastaut syndrome and Dravet syndrome—and other neurological diseases</li></ul><p><strong>Presenters</strong>:</p><p><strong>Jonathan J. Halford, MD</strong><br />Professor<br />Director, Translational Research Unit<br />Department of Neurology<br />Medical University of South Carolina<br />Charleston, SC</p><p><strong>H. Steve White, PhD</strong><br />Professor, Department of Pharmacy<br />Co-Director, Center for Epilepsy Drug Discovery<br />School of Pharmacy<br />University of Washington<br />Seattle, Washington</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="28038426" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/cbbecc39-610f-4018-82f9-cec8685b4ed8/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=cbbecc39-610f-4018-82f9-cec8685b4ed8&amp;feed=K2gejSy4"/>
      <itunes:title>Brain Cholesterol: The New Landscape of Neurological Disease Management</itunes:title>
      <itunes:author>Jonathan J. Halford MD, H. Steven White PhD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/f56a2062-7725-45df-9b25-745f5fccf548/3000x3000/neu-2023-epilepsy-am-podcast-icon.jpg?aid=rss_feed"/>
      <itunes:duration>00:29:01</itunes:duration>
      <itunes:summary>Expert faculty discuss the emerging role of brain cholesterol in the development and potential treatment of neurological diseases like epilepsy or Alzheimer and Huntington diseases. Learn what scientists know to date on brain cholesterol’s function in the body and pathogenesis for certain diseases as well as current research trends in developing novel, targeted treatments for pediatric epilepsy.</itunes:summary>
      <itunes:subtitle>Expert faculty discuss the emerging role of brain cholesterol in the development and potential treatment of neurological diseases like epilepsy or Alzheimer and Huntington diseases. Learn what scientists know to date on brain cholesterol’s function in the body and pathogenesis for certain diseases as well as current research trends in developing novel, targeted treatments for pediatric epilepsy.</itunes:subtitle>
      <itunes:keywords>developmental and epileptic encephalopathies, epilepsy, soticlestat, huntington’s disease, ds, dravet syndrome, lgs, psychiatry, alzheimer’s disease, neurology, brain cholesterol, dementia, jonathan j halford, dees, lennox-gastaut syndrome, h steve white, neurological disease</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>30</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">2d4da96d-60f5-465a-8b42-9102b73fde48</guid>
      <title>Defining Alzheimer’s Disease and MCI Management in the Modern Era</title>
      <description><![CDATA[<p>In this episode, Drs. Sabbagh and Isaacson discuss how to best approach Alzheimer’s disease (AD) and mild cognitive impairment (MCI) in clinical practice, including accurately diagnosing patients and optimizing treatment in terms of patient preferences and reimbursement options. The full episode covers:</p><ul><li>Defining AD and MCI and their clinical presentation</li><li>How to diagnose AD vs MCI</li><li>Reimbursement landscape for current diagnosing and monitoring tools</li><li>Precision medicine’s evolving role in diagnosing and treating patients with AD and/or MCI</li></ul><p> </p><p>Presenters:</p><p>Marwan Sabbagh, MD<br />Professor of Neurology<br />Alzheimer’s and Memory Disorders Division<br />Department of Neurology<br />Barrow Neurological Institute<br />Phoenix, Arizona</p><p>Richard Isaacson MD<br />Director of the Institute for Neurodegenerative Diseases<br />Florida</p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 31 Oct 2023 20:57:28 +0000</pubDate>
      <author>support@deceraclinical.com (Marwan Sabbagh MD, Richard Isaacson MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/defining-alzheimers-disease-and-mci-management-in-the-modern-era-7m_doP6_</link>
      <content:encoded><![CDATA[<p>In this episode, Drs. Sabbagh and Isaacson discuss how to best approach Alzheimer’s disease (AD) and mild cognitive impairment (MCI) in clinical practice, including accurately diagnosing patients and optimizing treatment in terms of patient preferences and reimbursement options. The full episode covers:</p><ul><li>Defining AD and MCI and their clinical presentation</li><li>How to diagnose AD vs MCI</li><li>Reimbursement landscape for current diagnosing and monitoring tools</li><li>Precision medicine’s evolving role in diagnosing and treating patients with AD and/or MCI</li></ul><p> </p><p>Presenters:</p><p>Marwan Sabbagh, MD<br />Professor of Neurology<br />Alzheimer’s and Memory Disorders Division<br />Department of Neurology<br />Barrow Neurological Institute<br />Phoenix, Arizona</p><p>Richard Isaacson MD<br />Director of the Institute for Neurodegenerative Diseases<br />Florida</p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="23914229" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/a48bd439-0ca9-49d6-9c51-e3c2fc94f5a6/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=a48bd439-0ca9-49d6-9c51-e3c2fc94f5a6&amp;feed=K2gejSy4"/>
      <itunes:title>Defining Alzheimer’s Disease and MCI Management in the Modern Era</itunes:title>
      <itunes:author>Marwan Sabbagh MD, Richard Isaacson MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/dc7c09c1-61de-489d-8f08-99d6a956a195/007ce29a-2d09-4763-b82f-f96167a40ab3/3000x3000/neu-2023-alzheimer-s-disease-me-podcast.jpg?aid=rss_feed"/>
      <itunes:duration>00:24:48</itunes:duration>
      <itunes:summary>Expert faculty discuss how to best approach Alzheimer’s disease and mild cognitive impairment in clinical practice, including accurately diagnosing patients and optimizing treatment in terms of patient preferences and reimbursement options. </itunes:summary>
      <itunes:subtitle>Expert faculty discuss how to best approach Alzheimer’s disease and mild cognitive impairment in clinical practice, including accurately diagnosing patients and optimizing treatment in terms of patient preferences and reimbursement options. </itunes:subtitle>
      <itunes:keywords>treatment, clinical education alliance, cco neuro pod, csf, cco, cco neurology podcast, amyloid pet, cea, diagnosis, psychiatry, clinical care options, alzheimer’s disease, neurology, mci, biomarkers, dementia, apoe, mild cognitive impairment, antimyloid agents, mab, neurological disease</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>31</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">1b655ebc-1ae2-47a3-9dd2-fe51105121f7</guid>
      <title>Keeping Up With the Treatment Landscape for MDD</title>
      <description><![CDATA[<p>The treatment landscape of major depression is increasingly shifting from monoaminergic agents to agents that modulate glutamate and GABA. Healthcare professionals need to stay up to date and educated on these changes in order to discuss the most current treatment options with their patients. In this podcast episode, we interview Dr Anita Clayton, a clinician researcher who has been involved in some of the clinical trials for these novel glutamatergic and GABAergic medications, and ask her key questions about mechanism of action and clinical application. Listeners will come away from this podcast episode more informed and more excited for the future of major depression care. </p><p><strong>Presenters:</strong></p><p><strong>Anita Clayton, MD</strong><br />David C. Wilson Professor and Chair<br />Department of Psychiatry and Neurobehavioral Sciences<br />Professor of Clinical Obstetrics and Gynecology<br />University of Virginia School of Medicine<br />Charlottesville, Virginia</p><p>This podcast episode is supported by an educational grant from Sage Therapeutics, Inc. and Biogen.</p><p>Link to full program:<br /><a href="https://bit.ly/3YdPMPa" target="_blank">https://bit.ly/3YdPMPa</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 1 Aug 2023 15:14:59 +0000</pubDate>
      <author>support@deceraclinical.com (Anita H. Clayton MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/novel-agents-c67NAb5p</link>
      <content:encoded><![CDATA[<p>The treatment landscape of major depression is increasingly shifting from monoaminergic agents to agents that modulate glutamate and GABA. Healthcare professionals need to stay up to date and educated on these changes in order to discuss the most current treatment options with their patients. In this podcast episode, we interview Dr Anita Clayton, a clinician researcher who has been involved in some of the clinical trials for these novel glutamatergic and GABAergic medications, and ask her key questions about mechanism of action and clinical application. Listeners will come away from this podcast episode more informed and more excited for the future of major depression care. </p><p><strong>Presenters:</strong></p><p><strong>Anita Clayton, MD</strong><br />David C. Wilson Professor and Chair<br />Department of Psychiatry and Neurobehavioral Sciences<br />Professor of Clinical Obstetrics and Gynecology<br />University of Virginia School of Medicine<br />Charlottesville, Virginia</p><p>This podcast episode is supported by an educational grant from Sage Therapeutics, Inc. and Biogen.</p><p>Link to full program:<br /><a href="https://bit.ly/3YdPMPa" target="_blank">https://bit.ly/3YdPMPa</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="27638279" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/d8aa8c76-532e-4f31-9560-6fee500bed9a/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=d8aa8c76-532e-4f31-9560-6fee500bed9a&amp;feed=K2gejSy4"/>
      <itunes:title>Keeping Up With the Treatment Landscape for MDD</itunes:title>
      <itunes:author>Anita H. Clayton MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/3c5d7c90-0775-4a1f-a082-fd9be5194781/3000x3000/psych-summit-mdd-prp6130-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:28:39</itunes:duration>
      <itunes:summary>Listen as Clinical Care Options talks with Dr Anita Clayton about advances in treatment options for major depression, with a focus on modulators of glutamate and GABA.</itunes:summary>
      <itunes:subtitle>Listen as Clinical Care Options talks with Dr Anita Clayton about advances in treatment options for major depression, with a focus on modulators of glutamate and GABA.</itunes:subtitle>
      <itunes:keywords>gaba, healthcare, esketamine, gabaergic, glutamate, depression, major depression, neurosteroids, psychiatry, glutamatergic, ketamine, pharmacology, zuranolone</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>28</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">063ec11b-4bb9-4f84-898d-a163a214b782</guid>
      <title>Rett Syndrome Tomorrow: Management Options on the Horizon</title>
      <description><![CDATA[<p>Rett syndrome is a rare but severe neurodevelopmental disorder, and current treatment approaches primarily focus on symptom management and supportive care. However, recent clinical developments are providing hope for a changing treatment landscape. In this podcast episode, experts in Rett syndrome David N. Lieberman, MD, PhD, and Jeffrey Neul, MD, PhD, discuss trofinetide and blarcamesine, 2 agents in late-stage clinical trials as treatment options for Rett syndrome. Throughout their conversation, Drs Lieberman and Neul review the pivotal LAVENDER, DAFFODIL, AVATAR, and EXCELLENCE trials, including information on the safety and efficacy profiles of trofinetide and blarcamesine. The experts end their discussion with a conversation about the potential roles of ketamine and gene therapy in the management of Rett syndrome.      </p><p><strong>Presenters:</strong></p><p><strong>David N. Lieberman, MD, PhD</strong><br />Instructor<br />Department of Neurology<br />Harvard Medical School<br />Attending Physician<br />Child Neurology<br />Boston Children’s Hospital<br />Boston, Massachusetts</p><p><strong>Jeffrey Neul, MD, PhD</strong><br />Director<br />Pediatrics<br />Vanderbilt University Medical Center<br />Nashville, Tennessee</p><p>This activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.</p><p>To claim CME/CE credit for this podcast, complete the posttest here:<br /> <a href="https://www.clinicaloptions.com/RettSyndrome" target="_blank">bit.ly/3JR4qq5</a>.</p><p>For additional activities in this program, visit<br /> <a href="https://www.clinicaloptions.com/RettSyndrome" target="_blank">bit.ly/3JR4qq5</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Mon, 27 Mar 2023 19:30:00 +0000</pubDate>
      <author>support@deceraclinical.com (David N. Lieberman MD PhD, Jeffrey Neul MD PhD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/rett-syndrome-tomorrow-management-options-on-the-horizon-HZpgDJTM</link>
      <content:encoded><![CDATA[<p>Rett syndrome is a rare but severe neurodevelopmental disorder, and current treatment approaches primarily focus on symptom management and supportive care. However, recent clinical developments are providing hope for a changing treatment landscape. In this podcast episode, experts in Rett syndrome David N. Lieberman, MD, PhD, and Jeffrey Neul, MD, PhD, discuss trofinetide and blarcamesine, 2 agents in late-stage clinical trials as treatment options for Rett syndrome. Throughout their conversation, Drs Lieberman and Neul review the pivotal LAVENDER, DAFFODIL, AVATAR, and EXCELLENCE trials, including information on the safety and efficacy profiles of trofinetide and blarcamesine. The experts end their discussion with a conversation about the potential roles of ketamine and gene therapy in the management of Rett syndrome.      </p><p><strong>Presenters:</strong></p><p><strong>David N. Lieberman, MD, PhD</strong><br />Instructor<br />Department of Neurology<br />Harvard Medical School<br />Attending Physician<br />Child Neurology<br />Boston Children’s Hospital<br />Boston, Massachusetts</p><p><strong>Jeffrey Neul, MD, PhD</strong><br />Director<br />Pediatrics<br />Vanderbilt University Medical Center<br />Nashville, Tennessee</p><p>This activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.</p><p>To claim CME/CE credit for this podcast, complete the posttest here:<br /> <a href="https://www.clinicaloptions.com/RettSyndrome" target="_blank">bit.ly/3JR4qq5</a>.</p><p>For additional activities in this program, visit<br /> <a href="https://www.clinicaloptions.com/RettSyndrome" target="_blank">bit.ly/3JR4qq5</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="21763873" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/41ff21f6-a086-4e88-a377-4b6e1fcd7f82/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=41ff21f6-a086-4e88-a377-4b6e1fcd7f82&amp;feed=K2gejSy4"/>
      <itunes:title>Rett Syndrome Tomorrow: Management Options on the Horizon</itunes:title>
      <itunes:author>David N. Lieberman MD PhD, Jeffrey Neul MD PhD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/3ebf6bac-44e1-4c51-b67d-1081dbf65e99/17dbdcab-566f-45bb-b1e0-7b0d129fd752/3000x3000/rett-syndrome-podcast3-prp5869-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:22:27</itunes:duration>
      <itunes:summary>Listen as David N. Lieberman, MD, PhD, and Jeffrey Neul, MD, PhD, discuss the efficacy and safety of emerging treatment options for Rett syndrome based on the latest clinical evidence.</itunes:summary>
      <itunes:subtitle>Listen as David N. Lieberman, MD, PhD, and Jeffrey Neul, MD, PhD, discuss the efficacy and safety of emerging treatment options for Rett syndrome based on the latest clinical evidence.</itunes:subtitle>
      <itunes:keywords>healthcare, epilepsy, treatment, neurodevelopmental, excellence trial, gene therapy, trofinetide, autism, avatar study, seizure, ce/cme, mecp2, rett, tripeptide analog, insulin growth factor-1, adverse events, physician assistant, methyl cpg binding protein 2, igf-1, neul, rett syndrome, daffodil trial, lavender trial, neurology, fda approval, nurse, lieberman, ketamine, mutations, genetic, blarcamesine, nurse practitioner, pharmacist, neurologist, rtt</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>26</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">c0ce110e-d5e9-4caa-9243-93fcbbd8ae64</guid>
      <title>Rett Syndrome Today: Current Options for Symptom Management</title>
      <description><![CDATA[<p>Rett syndrome affects many organ systems, and each patient has individual symptoms and experiences—there is no “one-size-fits-all” treatment approach. In this podcast episode, Rett syndrome experts David N. Lieberman, MD, PhD, and Shannon Standridge, DO, MPH, discuss some of the more common manifestations of Rett syndrome and current management strategies. While covering manifestations such as epilepsy, behavioral issues, and gastrointestinal distress, they highlight the value of a team approach to help the patient thrive. Throughout their conversation, Drs Lieberman and Standridge weave in real-world examples of interactions they have had with families of patients with Rett syndrome and offer insights on communication strategies for different aspects of management.</p><p>Presenters:</p><p><strong>David N. Lieberman MD, PhD</strong><br /><i>Instructor</i><br />Department of Neurology<br />Harvard Medical School<br /><i>Attending Physician</i><br />Child Neurology<br />Boston Children’s Hospital<br />Boston, Massachusetts</p><p><strong>Shannon Standridge, DO, MPH</strong><br /><i>Professor</i><br />Division of Neurology<br />Vinaya Rett Syndrome and Related Spectrum Disorders Clinic<br />Cincinnati Children’s Hospital Medical Center<br />Cincinnati, Ohio</p><p>This activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.</p><p>To claim CME/CE credit for this podcast, complete the posttest here: <br /><a href="http://bit.ly/41CeaeP" target="_blank">http://bit.ly/41CeaeP</a></p><p>For additional activities in this program, visit <br /><a href="http://bit.ly/3lXuzda" target="_blank">http://bit.ly/3lXuzda</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Thu, 2 Mar 2023 05:00:00 +0000</pubDate>
      <author>support@deceraclinical.com (David N. Lieberman MD PhD, Shannon Standridge DO MPH)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/rett-syndrome-today-current-options-for-symptom-management-Oo8Z5LcK</link>
      <content:encoded><![CDATA[<p>Rett syndrome affects many organ systems, and each patient has individual symptoms and experiences—there is no “one-size-fits-all” treatment approach. In this podcast episode, Rett syndrome experts David N. Lieberman, MD, PhD, and Shannon Standridge, DO, MPH, discuss some of the more common manifestations of Rett syndrome and current management strategies. While covering manifestations such as epilepsy, behavioral issues, and gastrointestinal distress, they highlight the value of a team approach to help the patient thrive. Throughout their conversation, Drs Lieberman and Standridge weave in real-world examples of interactions they have had with families of patients with Rett syndrome and offer insights on communication strategies for different aspects of management.</p><p>Presenters:</p><p><strong>David N. Lieberman MD, PhD</strong><br /><i>Instructor</i><br />Department of Neurology<br />Harvard Medical School<br /><i>Attending Physician</i><br />Child Neurology<br />Boston Children’s Hospital<br />Boston, Massachusetts</p><p><strong>Shannon Standridge, DO, MPH</strong><br /><i>Professor</i><br />Division of Neurology<br />Vinaya Rett Syndrome and Related Spectrum Disorders Clinic<br />Cincinnati Children’s Hospital Medical Center<br />Cincinnati, Ohio</p><p>This activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.</p><p>To claim CME/CE credit for this podcast, complete the posttest here: <br /><a href="http://bit.ly/41CeaeP" target="_blank">http://bit.ly/41CeaeP</a></p><p>For additional activities in this program, visit <br /><a href="http://bit.ly/3lXuzda" target="_blank">http://bit.ly/3lXuzda</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="31423703" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/f6ea554a-e209-473a-93c0-0a53174bfad4/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=f6ea554a-e209-473a-93c0-0a53174bfad4&amp;feed=K2gejSy4"/>
      <itunes:title>Rett Syndrome Today: Current Options for Symptom Management</itunes:title>
      <itunes:author>David N. Lieberman MD PhD, Shannon Standridge DO MPH</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/30cc66b4-07b6-47c5-af4b-fb2428decbbf/3000x3000/rett-syndrome-am-prp5869-podcast-v2-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:32:28</itunes:duration>
      <itunes:summary>Listen as David N. Lieberman, MD, PhD, and Shannon Standridge, DO, MPH, provide valuable information on current management strategies for common manifestations of Rett syndrome.</itunes:summary>
      <itunes:subtitle>Listen as David N. Lieberman, MD, PhD, and Shannon Standridge, DO, MPH, provide valuable information on current management strategies for common manifestations of Rett syndrome.</itunes:subtitle>
      <itunes:keywords>healthcare, epilepsy, repetitive movements, sleep, insomnia, neurodevelopmental, autism, music therapy, seizure, therapy, ce/cme, rett, respiratory, physician assistant, apraxic gait, ataxic gait, rett syndrome, neurology, abnormal breathing, nurse, regression, pharmacotherapy, developmental delay, genetic, nurse practitioner, gastrointestinal, pharmacist, neurologist, ssri, rtt</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>27</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">aa533a39-abf3-4fd4-8d76-8b545f8942a6</guid>
      <title>Rett Syndrome Today and Tomorrow: What Is Rett Syndrome?</title>
      <description><![CDATA[<p>In this podcast episode, experts in Rett syndrome, David N. Lieberman, MD, PhD, and Jeffrey Neul, MD, PhD, provide a comprehensive overview of Rett syndrome (RTT), a rare but severe neurodevelopmental disorder. They begin with a discussion on the clinical characteristics and typical disease progression of RTT before diving into the various genetic markers and how they may, or may not, be used in the diagnosis and prognosis. Finally, the experts ponder the future of RTT diagnoses, touching upon how we might identify RTT and intervene earlier, potential utilization of biomarkers, and the role of measurement-based care.</p><p>Presenters:</p><p><strong>David N. Lieberman MD, PhD</strong><br /><i>Instructor</i><br />Department of Neurology<br />Harvard Medical School<br /><i>Attending Physician</i><br />Child Neurology<br />Boston Children's Hospital<br />Boston, Massachusetts</p><p><strong>Jeffrey Neul MD, PhD</strong><br /><i>Director</i><br />Pediatrics<br />Vanderbilt University Medical Center<br />Nashville, Tennessee</p><p>This activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.</p><p>To claim CME/CE credit for this podcast, complete the posttest here:<br /><a href="https://bit.ly/3WjtMjA" target="_blank">https://bit.ly/3WjtMjA</a></p><p>For additional activities in this program, visit:<br /><a href="https://bit.ly/3kfAn0U" target="_blank">https://bit.ly/3kfAn0U</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 18 Jan 2023 21:30:00 +0000</pubDate>
      <author>support@deceraclinical.com (David Lieberman MD PhD, Jeffrey Neul MD PhD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/what-is-rett-syndrome-4Rfk5R28</link>
      <content:encoded><![CDATA[<p>In this podcast episode, experts in Rett syndrome, David N. Lieberman, MD, PhD, and Jeffrey Neul, MD, PhD, provide a comprehensive overview of Rett syndrome (RTT), a rare but severe neurodevelopmental disorder. They begin with a discussion on the clinical characteristics and typical disease progression of RTT before diving into the various genetic markers and how they may, or may not, be used in the diagnosis and prognosis. Finally, the experts ponder the future of RTT diagnoses, touching upon how we might identify RTT and intervene earlier, potential utilization of biomarkers, and the role of measurement-based care.</p><p>Presenters:</p><p><strong>David N. Lieberman MD, PhD</strong><br /><i>Instructor</i><br />Department of Neurology<br />Harvard Medical School<br /><i>Attending Physician</i><br />Child Neurology<br />Boston Children's Hospital<br />Boston, Massachusetts</p><p><strong>Jeffrey Neul MD, PhD</strong><br /><i>Director</i><br />Pediatrics<br />Vanderbilt University Medical Center<br />Nashville, Tennessee</p><p>This activity is supported by educational funding provided by Acadia Pharmaceuticals Inc.</p><p>To claim CME/CE credit for this podcast, complete the posttest here:<br /><a href="https://bit.ly/3WjtMjA" target="_blank">https://bit.ly/3WjtMjA</a></p><p>For additional activities in this program, visit:<br /><a href="https://bit.ly/3kfAn0U" target="_blank">https://bit.ly/3kfAn0U</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="28847885" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/596b9704-6980-4dd3-92a1-0b934fefa1de/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=596b9704-6980-4dd3-92a1-0b934fefa1de&amp;feed=K2gejSy4"/>
      <itunes:title>Rett Syndrome Today and Tomorrow: What Is Rett Syndrome?</itunes:title>
      <itunes:author>David Lieberman MD PhD, Jeffrey Neul MD PhD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/d5673901-b895-4031-8a4a-cda0d8a6275c/3000x3000/rett-syndrome-neu-pod628-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:29:49</itunes:duration>
      <itunes:summary>Listen as David N. Lieberman, MD, PhD, and Jeffrey Neul, MD, PhD, provide an overview of Rett syndrome, including clinical characteristics, disease progression, and genetic considerations.</itunes:summary>
      <itunes:subtitle>Listen as David N. Lieberman, MD, PhD, and Jeffrey Neul, MD, PhD, provide an overview of Rett syndrome, including clinical characteristics, disease progression, and genetic considerations.</itunes:subtitle>
      <itunes:keywords>healthcare, epilepsy, repetitive movements, neurodevelopmental, autism, seizure, foxg1, ce/cme, mecp2, rett, physician assistant, apraxic gait, methyl cpg binding protein 2, cdkl5, ataxic gait, rett syndrome, neurology, nurse, regression, phenotype, developmental delay, mutations, genetic, nurse practitioner, pharmacist, neurologist, rtt</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>24</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">f89e5429-24a3-41f2-92f2-ff80fc376a70</guid>
      <title>Long-term Solutions for Long-term Diseases: Using Long-Acting Injectable Antipsychotics in Practice</title>
      <description><![CDATA[<p>In this podcast episode, Leslie Citrome, MD, MPH, and Adam Lowy, MD, share a wealth of knowledge about long-acting injectable (LAI) antipsychotics. Their conversation begins with an overview of the pharmacokinetic profiles of LAI antipsychotics and how they differ from their oral counterparts, as well as injection intervals available with current formulations. The experts also discuss the clinical utility of LAI antipsychotics in psychiatry practice, highlighting their role in assuring medication adherence and their application in both first- and later-episode psychosis. Finally, Drs Citrome and Lowy hit on practical aspects of incorporating LAI antipsychotics into patient care: communicating with patients to dispel myths and stigma surrounding injectable medications, identifying injection resources in your medical community, and strategies to navigate insurance barriers.</p><p>Throughout the podcast, Drs Citrome and Lowy reference several links to outside sources that can provide valuable education on LAI antipsychotics. Those links are listed below for your convenience.</p><p>Administering LAI Into Dorsal Gluteal Site: <br /><a href="https://bit.ly/3XjSm5a" target="_blank">https://bit.ly/3XjSm5a</a></p><p>Administering LAI Into Deltoid Site: <br /><a href="https://bit.ly/3Xlyq1L" target="_blank">https://bit.ly/3Xlyq1L</a></p><p>Administering LAI Into Abdominal Site: <br /><a href="https://bit.ly/3wgGJ2Z" target="_blank">https://bit.ly/3wgGJ2Z</a></p><p>Presenters:</p><p><strong>Leslie Citrome, MD, MPH</strong><br /><i>Clinical Professor</i><br />Department of Psychiatry and Behavioral Sciences<br />New York Medical College<br />Valhalla, New York</p><p><strong>Adam Lowy, MD</strong><br /><i>Staff Psychiatrist</i><br />Ellenhorn<br />Los Angeles, California<br /><br />This activity is supported by educational funding provided byOtsuka America Pharmaceutical, Inc. and Lundbeck.</p><p>For additional activities in this program, visit:<br /><a href="https://bit.ly/3iM0HiP" target="_blank">https://bit.ly/3iM0HiP</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 18 Jan 2023 21:30:00 +0000</pubDate>
      <author>support@deceraclinical.com (Leslie Citrome MD MPH, Adam Lowy MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/using-lai-antipsychotics-dBYs3tF3</link>
      <content:encoded><![CDATA[<p>In this podcast episode, Leslie Citrome, MD, MPH, and Adam Lowy, MD, share a wealth of knowledge about long-acting injectable (LAI) antipsychotics. Their conversation begins with an overview of the pharmacokinetic profiles of LAI antipsychotics and how they differ from their oral counterparts, as well as injection intervals available with current formulations. The experts also discuss the clinical utility of LAI antipsychotics in psychiatry practice, highlighting their role in assuring medication adherence and their application in both first- and later-episode psychosis. Finally, Drs Citrome and Lowy hit on practical aspects of incorporating LAI antipsychotics into patient care: communicating with patients to dispel myths and stigma surrounding injectable medications, identifying injection resources in your medical community, and strategies to navigate insurance barriers.</p><p>Throughout the podcast, Drs Citrome and Lowy reference several links to outside sources that can provide valuable education on LAI antipsychotics. Those links are listed below for your convenience.</p><p>Administering LAI Into Dorsal Gluteal Site: <br /><a href="https://bit.ly/3XjSm5a" target="_blank">https://bit.ly/3XjSm5a</a></p><p>Administering LAI Into Deltoid Site: <br /><a href="https://bit.ly/3Xlyq1L" target="_blank">https://bit.ly/3Xlyq1L</a></p><p>Administering LAI Into Abdominal Site: <br /><a href="https://bit.ly/3wgGJ2Z" target="_blank">https://bit.ly/3wgGJ2Z</a></p><p>Presenters:</p><p><strong>Leslie Citrome, MD, MPH</strong><br /><i>Clinical Professor</i><br />Department of Psychiatry and Behavioral Sciences<br />New York Medical College<br />Valhalla, New York</p><p><strong>Adam Lowy, MD</strong><br /><i>Staff Psychiatrist</i><br />Ellenhorn<br />Los Angeles, California<br /><br />This activity is supported by educational funding provided byOtsuka America Pharmaceutical, Inc. and Lundbeck.</p><p>For additional activities in this program, visit:<br /><a href="https://bit.ly/3iM0HiP" target="_blank">https://bit.ly/3iM0HiP</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="28104867" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/b14480a8-a14a-4df7-a88d-d6a984dfbd69/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=b14480a8-a14a-4df7-a88d-d6a984dfbd69&amp;feed=K2gejSy4"/>
      <itunes:title>Long-term Solutions for Long-term Diseases: Using Long-Acting Injectable Antipsychotics in Practice</itunes:title>
      <itunes:author>Leslie Citrome MD MPH, Adam Lowy MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/70b6c56e-887d-4a85-8cf1-69a8fba020e7/3000x3000/psychorx-lai-neu-pod651-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:29:04</itunes:duration>
      <itunes:summary>Listen as Leslie Citrome, MD, MPH, and Adam Lowy, MD, share information on long-acting injectable antipsychotics ranging from pharmacokinetic properties to strategies on incorporating these agents into clinical practice.</itunes:summary>
      <itunes:subtitle>Listen as Leslie Citrome, MD, MPH, and Adam Lowy, MD, share information on long-acting injectable antipsychotics ranging from pharmacokinetic properties to strategies on incorporating these agents into clinical practice.</itunes:subtitle>
      <itunes:keywords>healthcare, second generation antipsychotic, fluphenazine, schizophrenia, first generation antipsychotic, aripiprazole, long-acting injectables, assertive community treatment, psychiatry, haloperidol, injection, risperidone, psychiatrist, pharmacokinetics, subcutaneous, act, lai antipsychotics, pharmacist, adherence, intramuscular, antipsychotics</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>25</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">56f85394-1312-4179-b2c2-9ab0859e30c7</guid>
      <title>To the Rescue: Incorporating Rescue Medications Into Epilepsy Treatment Plans</title>
      <description><![CDATA[<p>In this podcast episode, epileptologists Aatif Husain, MD, and John Stern, MD, have a conversation about rescue therapies and how they fit into the spectrum of epilepsy management. Their discussion begins with sharing what they consider the utility of rescue therapies to be in the overall spectrum of epilepsy. As the conversation goes on, they address the role of rescue therapies in more specific patient populations, such as the newly diagnosed patient, a patient experiencing seizure clusters, and patients who may be experiencing either very few or relatively many breakthrough seizure events. In all scenarios, the experts relate the use of rescue therapies as “insurance”—hoping that the agents don’t have to be used, but having them available as coverage in the worst-case scenario. The podcast goes on to discuss rescue therapies in terms of available routes and mechanisms of action and practical strategies for talking to patients about these agents. Rounding out the episode, Drs Husain and Stern express their hopes for future developments in epilepsy management.</p><p>Presenters:</p><p><strong>Aatif Husain, MD</strong><br /><i>Professor</i><br />Division of Epilepsy, Sleep and Clinical Neurophysiology<br />Department of Neurology<br />Duke University Medical Center<br />Durham, North Carolina</p><p><strong>John Stern, MD</strong><br /><i>Professor</i><br />Neurology<br />Geffen School of Medicine, UCLA<br /><i>Director</i><br />Epilepsy Clinical Program<br />UCLA Department of Neurology<br />Los Angeles, California</p><p>This content is based on a CE/CME program supported by an independent educational grant from Neurelis, Inc.</p><p>For additional activities in this program, visit<br /> <a href="https://bit.ly/3GiLlu4" target="_blank">https://bit.ly/3GiLlu4</a>.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 4 Jan 2023 21:10:00 +0000</pubDate>
      <author>support@deceraclinical.com (Aatif Husain MD, John Stern MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/rescue-therapies-in-epilepsy-3SyjP4Xp</link>
      <content:encoded><![CDATA[<p>In this podcast episode, epileptologists Aatif Husain, MD, and John Stern, MD, have a conversation about rescue therapies and how they fit into the spectrum of epilepsy management. Their discussion begins with sharing what they consider the utility of rescue therapies to be in the overall spectrum of epilepsy. As the conversation goes on, they address the role of rescue therapies in more specific patient populations, such as the newly diagnosed patient, a patient experiencing seizure clusters, and patients who may be experiencing either very few or relatively many breakthrough seizure events. In all scenarios, the experts relate the use of rescue therapies as “insurance”—hoping that the agents don’t have to be used, but having them available as coverage in the worst-case scenario. The podcast goes on to discuss rescue therapies in terms of available routes and mechanisms of action and practical strategies for talking to patients about these agents. Rounding out the episode, Drs Husain and Stern express their hopes for future developments in epilepsy management.</p><p>Presenters:</p><p><strong>Aatif Husain, MD</strong><br /><i>Professor</i><br />Division of Epilepsy, Sleep and Clinical Neurophysiology<br />Department of Neurology<br />Duke University Medical Center<br />Durham, North Carolina</p><p><strong>John Stern, MD</strong><br /><i>Professor</i><br />Neurology<br />Geffen School of Medicine, UCLA<br /><i>Director</i><br />Epilepsy Clinical Program<br />UCLA Department of Neurology<br />Los Angeles, California</p><p>This content is based on a CE/CME program supported by an independent educational grant from Neurelis, Inc.</p><p>For additional activities in this program, visit<br /> <a href="https://bit.ly/3GiLlu4" target="_blank">https://bit.ly/3GiLlu4</a>.</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="27077793" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/99524d52-9b93-4531-8313-1463d8459d6d/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=99524d52-9b93-4531-8313-1463d8459d6d&amp;feed=K2gejSy4"/>
      <itunes:title>To the Rescue: Incorporating Rescue Medications Into Epilepsy Treatment Plans</itunes:title>
      <itunes:author>Aatif Husain MD, John Stern MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/3ebf6bac-44e1-4c51-b67d-1081dbf65e99/cb4c2a9a-0f68-4e50-af30-7be1854d610d/3000x3000/pod617-movement-do-epilepsy-podcast.jpg?aid=rss_feed"/>
      <itunes:duration>00:28:03</itunes:duration>
      <itunes:summary>Listen as Aatif Husain, MD, and John Stern, MD, discuss the role of rescue therapies in the spectrum of epilepsy management.</itunes:summary>
      <itunes:subtitle>Listen as Aatif Husain, MD, and John Stern, MD, discuss the role of rescue therapies in the spectrum of epilepsy management.</itunes:subtitle>
      <itunes:keywords>healthcare, epileptologist, epilepsy, midazolam, tonic clonic, seizure, acute management, seizure cluster, intranasal, diazepam, benzodiazepine, neurology, breakthrough seizure, rescue therapy, grand mal, neurologist, chronic management</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>23</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">5ab25a84-f5f5-466a-938d-5d78c6d768df</guid>
      <title>Halting Hallucinations: A Discussion of Management Strategies for Parkinson’s Disease Psychosis</title>
      <description><![CDATA[<p>In this podcast episode, Marwan Sabbagh, MD, FAAN, and Marta San Luciano, MD, MS, FAAN, have a conversation about Parkinson’s disease psychosis (PDP). Their discussion provides information on the disease itself—covering symptoms, risk factors, and mechanism—before moving into clinical strategies for diagnosis and disease and comorbidity management. The experts emphasize the importance of ruling out an underlying cause of psychosis before making a diagnosis of PDP, calling out common culprits such as urinary and respiratory tract infections. Following diagnosis, they comment on the value of implementing nonpharmacologic measures in tandem with pharmacologic interventions for PDP. Within the discussion of pharmacologic interventions, Drs Sabbagh and San Luciano give a well-rounded explanation of patient and medication factors they consider when choosing a treatment for their patients with PDP, including patient outcomes they have experienced in clinical practice. Rounding out the podcast, the experts touch on their approach to managing the very common comorbidity of sleep disturbances in patients with PDP.</p><p>Presenters:</p><p><strong>Marwan Sabbagh, MD, FAAN</strong><br /><i>Professor of Neurology</i><br />Alzheimer's and Memory Disorders Division<br />Department of Neurology<br />Barrow Neurological Institute<br />Phoenix, Arizona</p><p><strong>Marta San Luciano, MD, MS, FAAN</strong><br /><i>Associate Professor of Neurology</i><br />University of California, San Francisco<br /><i>Attending Neurologist</i><br />Neurology/Movement Disorders and Neuromodulation Center<br />University of California, San Francisco Medical Center<br />San Francisco, California</p><p>This content is based on a CE/CME program supported by an independent educational grant from Acadia Pharmaceuticals, Inc.</p><p>For additional activities in this program, visit<br /><a href="http://bit.ly/3tPMqnr" target="_blank">http://bit.ly/3tPMqnr</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 4 Jan 2023 16:00:00 +0000</pubDate>
      <author>support@deceraclinical.com (Marwan Sabbagh MD FAAN, Marta San Luciano MD MS FAAN)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/halting-hallucinations-a-discussion-of-management-strategies-for-parkinsons-disease-psychosis-VwN803fF</link>
      <content:encoded><![CDATA[<p>In this podcast episode, Marwan Sabbagh, MD, FAAN, and Marta San Luciano, MD, MS, FAAN, have a conversation about Parkinson’s disease psychosis (PDP). Their discussion provides information on the disease itself—covering symptoms, risk factors, and mechanism—before moving into clinical strategies for diagnosis and disease and comorbidity management. The experts emphasize the importance of ruling out an underlying cause of psychosis before making a diagnosis of PDP, calling out common culprits such as urinary and respiratory tract infections. Following diagnosis, they comment on the value of implementing nonpharmacologic measures in tandem with pharmacologic interventions for PDP. Within the discussion of pharmacologic interventions, Drs Sabbagh and San Luciano give a well-rounded explanation of patient and medication factors they consider when choosing a treatment for their patients with PDP, including patient outcomes they have experienced in clinical practice. Rounding out the podcast, the experts touch on their approach to managing the very common comorbidity of sleep disturbances in patients with PDP.</p><p>Presenters:</p><p><strong>Marwan Sabbagh, MD, FAAN</strong><br /><i>Professor of Neurology</i><br />Alzheimer's and Memory Disorders Division<br />Department of Neurology<br />Barrow Neurological Institute<br />Phoenix, Arizona</p><p><strong>Marta San Luciano, MD, MS, FAAN</strong><br /><i>Associate Professor of Neurology</i><br />University of California, San Francisco<br /><i>Attending Neurologist</i><br />Neurology/Movement Disorders and Neuromodulation Center<br />University of California, San Francisco Medical Center<br />San Francisco, California</p><p>This content is based on a CE/CME program supported by an independent educational grant from Acadia Pharmaceuticals, Inc.</p><p>For additional activities in this program, visit<br /><a href="http://bit.ly/3tPMqnr" target="_blank">http://bit.ly/3tPMqnr</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="23285850" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/249e3629-158c-4957-893d-89da454b62e8/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=249e3629-158c-4957-893d-89da454b62e8&amp;feed=K2gejSy4"/>
      <itunes:title>Halting Hallucinations: A Discussion of Management Strategies for Parkinson’s Disease Psychosis</itunes:title>
      <itunes:author>Marwan Sabbagh MD FAAN, Marta San Luciano MD MS FAAN</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/6f402e9a-eac4-455d-8334-2996f9c0edae/c8416f32-1963-46ad-8462-93b584c8b520/3000x3000/movement-do-pd-dementia-podcasticon.jpg?aid=rss_feed"/>
      <itunes:duration>00:24:09</itunes:duration>
      <itunes:summary>Listen as Marwan Sabbagh, MD, FAAN, and Marta San Luciano, MD, MS, FAAN, discuss clinical strategies for diagnosing and managing Parkinson’s disease psychosis.</itunes:summary>
      <itunes:subtitle>Listen as Marwan Sabbagh, MD, FAAN, and Marta San Luciano, MD, MS, FAAN, discuss clinical strategies for diagnosing and managing Parkinson’s disease psychosis.</itunes:subtitle>
      <itunes:keywords>healthcare, quetiapine, clozapine, neuropsychiatric, hallucinations, patient care, pimavanserin, parkinson’s disease, dopamine, psychiatry, parkinson’s disease psychosis, neurology, delusions, psychosis, dementia, psychotic, cognitive impairment</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>19</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">551918fe-71cb-40b5-a779-2ee56bc49492</guid>
      <title>Tardive Dyskinesia Etiology: Risks and Considerations</title>
      <description><![CDATA[<p>In this episode, Christoph U. Correll, MD, and John M. Kane, MD, discuss the various etiologies of tardive dyskinesia (TD). Although most healthcare professionals are aware of the risk for TD that comes with first- and second-generation antipsychotic use, there is less awareness around other modifiable and unmodifiable factors that increase risk for TD development. Some modifiable risks include metoclopramide use, anticholinergic use, and substance use disorder; unmodifiable risks include older age and female sex. The doctors agree that, regardless of the level of risk, careful documentation and evaluation should be conducted with patients to detect TD early—should it develop. Their conversation rounds out with considerations for treatment approaches and clinical pearls garnered from years in practice.</p><p>Presenters:<br /><strong>Christoph U. Correll, MD</strong><br /><i>Professor of Psychiatry and Molecular Medicine</i><br />The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell<br />New York, New York<br /><i>Professor of Child and Adolescent Psychiatry</i><br />Charité – Universitätsmedizin Berlin<br />Berlin, Germany</p><p><strong>John M. Kane, MD</strong><br /><i>Vice President for Behavioral Health Services</i><br />Northwell Health<br /><i>Chairman of Psychiatry</i><br />Zucker Hillside Hospital<br />Queens, New York<br /><i>Chairman of Psychiatry</i><br /><i>Professor of Psychiatry and Molecular Medicine</i><br />Zucker School of Medicine at Hofstra/Northwell<br />Hempstead, New York</p><p>For more programs in this series, visit:<br /><a href="https://bit.ly/3AhRXau" target="_blank">https://bit.ly/3AhRXau</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Thu, 29 Dec 2022 21:50:00 +0000</pubDate>
      <author>support@deceraclinical.com (Christoph U Correll MD, John M Kane MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/tardive-dyskinesia-etiology-risks-and-considerations-0f5Hjm66</link>
      <content:encoded><![CDATA[<p>In this episode, Christoph U. Correll, MD, and John M. Kane, MD, discuss the various etiologies of tardive dyskinesia (TD). Although most healthcare professionals are aware of the risk for TD that comes with first- and second-generation antipsychotic use, there is less awareness around other modifiable and unmodifiable factors that increase risk for TD development. Some modifiable risks include metoclopramide use, anticholinergic use, and substance use disorder; unmodifiable risks include older age and female sex. The doctors agree that, regardless of the level of risk, careful documentation and evaluation should be conducted with patients to detect TD early—should it develop. Their conversation rounds out with considerations for treatment approaches and clinical pearls garnered from years in practice.</p><p>Presenters:<br /><strong>Christoph U. Correll, MD</strong><br /><i>Professor of Psychiatry and Molecular Medicine</i><br />The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell<br />New York, New York<br /><i>Professor of Child and Adolescent Psychiatry</i><br />Charité – Universitätsmedizin Berlin<br />Berlin, Germany</p><p><strong>John M. Kane, MD</strong><br /><i>Vice President for Behavioral Health Services</i><br />Northwell Health<br /><i>Chairman of Psychiatry</i><br />Zucker Hillside Hospital<br />Queens, New York<br /><i>Chairman of Psychiatry</i><br /><i>Professor of Psychiatry and Molecular Medicine</i><br />Zucker School of Medicine at Hofstra/Northwell<br />Hempstead, New York</p><p>For more programs in this series, visit:<br /><a href="https://bit.ly/3AhRXau" target="_blank">https://bit.ly/3AhRXau</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="20003246" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/fc8ed4a3-41a1-4c5f-aeb8-80677dd3250d/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=fc8ed4a3-41a1-4c5f-aeb8-80677dd3250d&amp;feed=K2gejSy4"/>
      <itunes:title>Tardive Dyskinesia Etiology: Risks and Considerations</itunes:title>
      <itunes:author>Christoph U Correll MD, John M Kane MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/6f402e9a-eac4-455d-8334-2996f9c0edae/fd86080b-f316-4b97-9131-ebc8bfc46c03/3000x3000/sy-tardive-dyskinesia-podcast-icon-6.jpg?aid=rss_feed"/>
      <itunes:duration>00:20:44</itunes:duration>
      <itunes:summary>Listen to this interprofessional discussion of the various risk factors for tardive dyskinesia—including those beyond antipsychotic use—and how the etiology of the disease might impact treatment approach. </itunes:summary>
      <itunes:subtitle>Listen to this interprofessional discussion of the various risk factors for tardive dyskinesia—including those beyond antipsychotic use—and how the etiology of the disease might impact treatment approach. </itunes:subtitle>
      <itunes:keywords>healthcare, tardive dyskinesia, anticholinergics, deutetrabenazine, vmat2 inhibitors, dopamine, risk factors, psychiatry, aims exam, neurology, psychiatrist, vesicular monoamine transporter 2, movement disorder, valbenazine, neurologist, antipsychotics</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>22</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">bbe01d63-bdc3-4b06-88e6-00c850ee2d91</guid>
      <title>Bipolar Disorder Research to Look For in 2023</title>
      <description><![CDATA[<p>In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, have a conversation about the ongoing bipolar disorder research and developments expected to have an impact in the coming year. They elaborate on the various  neurotransmitters being investigated and how this research might change the future of patient care. From investigating new mechanisms of action to increased uptake of more novel therapeutics such as esketamine and neuromodulation, there is a lot to look forward to. As they note in the podcast: It’s an exciting time to be in the field of brain science!</p><p>Presenters:<br /><strong>Greg W. Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p><strong>Vladimir Maletic MD</strong><br /><i>Clinical Professor</i><br />Department of Psychiatry<br />USC School of Medicine<br />Greenville, South Carolina</p><p>This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.</p><p>For more programs in this series, visit:<br /><a href="https://bit.ly/3ft1rYI" target="_blank">https://bit.ly/3ft1rYI</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 7 Dec 2022 21:30:00 +0000</pubDate>
      <author>support@deceraclinical.com (Greg W. Mattingly MD, Vladimir Maletic MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/bipolar-disorder-research-to-look-for-in-2023-6NFPhimJ</link>
      <content:encoded><![CDATA[<p>In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, have a conversation about the ongoing bipolar disorder research and developments expected to have an impact in the coming year. They elaborate on the various  neurotransmitters being investigated and how this research might change the future of patient care. From investigating new mechanisms of action to increased uptake of more novel therapeutics such as esketamine and neuromodulation, there is a lot to look forward to. As they note in the podcast: It’s an exciting time to be in the field of brain science!</p><p>Presenters:<br /><strong>Greg W. Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p><strong>Vladimir Maletic MD</strong><br /><i>Clinical Professor</i><br />Department of Psychiatry<br />USC School of Medicine<br />Greenville, South Carolina</p><p>This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.</p><p>For more programs in this series, visit:<br /><a href="https://bit.ly/3ft1rYI" target="_blank">https://bit.ly/3ft1rYI</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="23150535" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/2bde1bb9-e57d-4048-b1ed-0adb15cc67ff/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=2bde1bb9-e57d-4048-b1ed-0adb15cc67ff&amp;feed=K2gejSy4"/>
      <itunes:title>Bipolar Disorder Research to Look For in 2023</itunes:title>
      <itunes:author>Greg W. Mattingly MD, Vladimir Maletic MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/6f402e9a-eac4-455d-8334-2996f9c0edae/81f51697-5d5c-446a-ace8-566e88a08930/3000x3000/pod468-bipolar-depression-additional-podcast-06.jpg?aid=rss_feed"/>
      <itunes:duration>00:24:05</itunes:duration>
      <itunes:summary>Listen as 2 experts in psychiatry summarize the bipolar disorder research and developments to look forward to in the coming year.</itunes:summary>
      <itunes:subtitle>Listen as 2 experts in psychiatry summarize the bipolar disorder research and developments to look forward to in the coming year.</itunes:subtitle>
      <itunes:keywords>gaba, healthcare, nmda, esketamine, glutamate, genetics, bipolar spectrum, physician assistant, bipolar disorder, mental health, taar1, transcranial magnetic stimulation, dopamine, neurotransmitters, digital therapeutics, psychiatry, neuroscience, brain, second-generation antipsychotic, clinician, tms, first-generation antipsychotic, trace amine-associated receptor 1, bipolar depression, ketamine, nurse practitioner, serotonin, physician, mood disorders, antipsychotics</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>21</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">e455559c-de42-4240-b755-02235b25561d</guid>
      <title>Answering Your Questions About Tardive Dyskinesia</title>
      <description><![CDATA[<p>Get answers to the questions that you and your colleagues have asked! In this episode, Jonathan M. Meyer, MD; Leslie Citrome, MD, MPH; and Stuart Isaacson, MD, provide answers to audience questions that were submitted at recent CCO Psychiatry meetings. Their thoughtful responses cover your questions on screening, communicating with patients, medication management, and more. Moderators Rajesh Pahwa, MD; Charles DeBattista, DMH, MD; and Greg W. Mattingly, MD, provide complementary commentary throughout the question and answer session, adding interprofessional perspective to the activity.</p><p>Presenters:</p><p><strong>Leslie Citrome, MD, MPH</strong><br /><i>Clinical Professor</i><br />Department of Psychiatry and Behavioral Sciences<br />New York Medical College<br />Valhalla, New York</p><p><strong>Charles DeBattista, DMH, MD</strong><br /><i>Chief</i><br />Depression Research Clinic<br /><i>Director</i><br />Medical Student Education in Psychiatry<br /><i>Professor of Psychiatry and Behavioral Sciences</i><br />Stanford University School of Medicine<br />Stanford, California</p><p><strong>Stuart Isaacson, MD</strong><br /><i>Director</i><br />Parkinson's Disease and Movement Disorders Center of Boca Raton<br />Boca Raton, Florida<br /><i>Clinical Associate Professor of Neurology</i><br />FIU Herbert Wertheim College of Medicine<br />Miami, Florida</p><p><strong>Greg W. Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p><strong>Jonathan M. Meyer MD</strong><br /><i>Voluntary Clinical Professor</i>, Department of Psychiatry<br />University of California, San Diego<br /><i>Psychopharmacology Consultant</i><br />Balboa Naval Medical Center First Episode Psychosis Program<br />State of Nevada Project ECHO First Episode Psychosis Program</p><p><strong>Rajesh Pahwa, MD</strong><br /><i>Chief,</i> Parkinson and Movement Disorder Division<br /><i>Director</i>, Parkinson Foundation Center of Excellence<br />University of Kansas Medical Center<br />Kansas City, Kansas</p><p>For more programs in this series, visit: <br /><a href="https://bit.ly/3Bg0oTv" target="_blank">https://bit.ly/3Bg0oTv</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 6 Dec 2022 21:30:00 +0000</pubDate>
      <author>support@deceraclinical.com (Leslie Citrome MD MPH, Charles DeBattista DMH MD, Stuart Isaacson MD, Greg Mattingly MD, Jonathan Meyer MD, Rajesh Pahwa MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/tardive-dyskinesia-faq-cjxpZsJ9</link>
      <content:encoded><![CDATA[<p>Get answers to the questions that you and your colleagues have asked! In this episode, Jonathan M. Meyer, MD; Leslie Citrome, MD, MPH; and Stuart Isaacson, MD, provide answers to audience questions that were submitted at recent CCO Psychiatry meetings. Their thoughtful responses cover your questions on screening, communicating with patients, medication management, and more. Moderators Rajesh Pahwa, MD; Charles DeBattista, DMH, MD; and Greg W. Mattingly, MD, provide complementary commentary throughout the question and answer session, adding interprofessional perspective to the activity.</p><p>Presenters:</p><p><strong>Leslie Citrome, MD, MPH</strong><br /><i>Clinical Professor</i><br />Department of Psychiatry and Behavioral Sciences<br />New York Medical College<br />Valhalla, New York</p><p><strong>Charles DeBattista, DMH, MD</strong><br /><i>Chief</i><br />Depression Research Clinic<br /><i>Director</i><br />Medical Student Education in Psychiatry<br /><i>Professor of Psychiatry and Behavioral Sciences</i><br />Stanford University School of Medicine<br />Stanford, California</p><p><strong>Stuart Isaacson, MD</strong><br /><i>Director</i><br />Parkinson's Disease and Movement Disorders Center of Boca Raton<br />Boca Raton, Florida<br /><i>Clinical Associate Professor of Neurology</i><br />FIU Herbert Wertheim College of Medicine<br />Miami, Florida</p><p><strong>Greg W. Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p><strong>Jonathan M. Meyer MD</strong><br /><i>Voluntary Clinical Professor</i>, Department of Psychiatry<br />University of California, San Diego<br /><i>Psychopharmacology Consultant</i><br />Balboa Naval Medical Center First Episode Psychosis Program<br />State of Nevada Project ECHO First Episode Psychosis Program</p><p><strong>Rajesh Pahwa, MD</strong><br /><i>Chief,</i> Parkinson and Movement Disorder Division<br /><i>Director</i>, Parkinson Foundation Center of Excellence<br />University of Kansas Medical Center<br />Kansas City, Kansas</p><p>For more programs in this series, visit: <br /><a href="https://bit.ly/3Bg0oTv" target="_blank">https://bit.ly/3Bg0oTv</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="21935627" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/ea3e704f-d36b-4477-ba59-a7f0614cd831/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=ea3e704f-d36b-4477-ba59-a7f0614cd831&amp;feed=K2gejSy4"/>
      <itunes:title>Answering Your Questions About Tardive Dyskinesia</itunes:title>
      <itunes:author>Leslie Citrome MD MPH, Charles DeBattista DMH MD, Stuart Isaacson MD, Greg Mattingly MD, Jonathan Meyer MD, Rajesh Pahwa MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/0dbb892d-f27e-4bd8-91a3-a1db94bdd318/3000x3000/pod472-sy-tardive-dyskinesia-podcast-neurocrine-5.jpg?aid=rss_feed"/>
      <itunes:duration>00:22:48</itunes:duration>
      <itunes:summary>Following recent live conferences, expert faculty answer your most asked questions on tardive dyskinesia screening and management.</itunes:summary>
      <itunes:subtitle>Following recent live conferences, expert faculty answer your most asked questions on tardive dyskinesia screening and management.</itunes:subtitle>
      <itunes:keywords>healthcare, tardive dyskinesia, anticholinergics, deutetrabenazine, vmat2 inhibitors, dopamine, psychiatry, aims exam, neurology, psychiatrist, benztropine, vesicular monoamine transporter 2, movement disorder, valbenazine, amantadine, neurologist, antipsychotics</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>20</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">2db2882e-a7ee-4820-b4b0-cd717e40240f</guid>
      <title>Symptom Management in Bipolar Depression: Realistic Expectations and Strategies for Improvement</title>
      <description><![CDATA[<p>In this episode, Joseph F. Goldberg, MD, and Roger McIntyre, MD, FRCPC, shed light on the symptom improvement timeline in bipolar depression. This is a topic made more complex when factoring in individual patient characteristics and comorbidities, but the 2 experts have astute insights on how to tailor a management plan based on such factors. They cover symptom management and improvement from a variety of angles, including evaluating improvement in functionality and mood, guidance on follow-up and dose adjustment schedules, the utility of measurement-based care, and—of most importance—how to best communicate with and support a patient while they work towards remission and recovery.</p><p>Presenters:</p><p><strong>Joseph F. Goldberg, MD</strong><br /><i>Clinical Professor of Psychiatry</i><br />Department of Psychiatry<br />Icahn School of Medicine at Mount Sinai<br />New York, New York</p><p><strong>Roger McIntyre, MD, FRCPC</strong><br /><i>Professor of Psychiatry and Pharmacology</i><br />Department of Psychiatry/Pharmacology<br />University of Toronto<br /><i>Head</i>, Mood Disorders Psychopharmacology Unit<br />Department of Psychiatry<br />Toronto, Canada</p><p>This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.</p><p>For more programs in this series, visit:<br /><a href="https://bit.ly/3ft1rYI" target="_blank">https://bit.ly/3ft1rYI</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 1 Nov 2022 20:30:00 +0000</pubDate>
      <author>support@deceraclinical.com (Joseph F. Goldberg MD, Roger McIntyre MD FRCPC)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/bipolar-symptom-management-kHVuYQLL</link>
      <content:encoded><![CDATA[<p>In this episode, Joseph F. Goldberg, MD, and Roger McIntyre, MD, FRCPC, shed light on the symptom improvement timeline in bipolar depression. This is a topic made more complex when factoring in individual patient characteristics and comorbidities, but the 2 experts have astute insights on how to tailor a management plan based on such factors. They cover symptom management and improvement from a variety of angles, including evaluating improvement in functionality and mood, guidance on follow-up and dose adjustment schedules, the utility of measurement-based care, and—of most importance—how to best communicate with and support a patient while they work towards remission and recovery.</p><p>Presenters:</p><p><strong>Joseph F. Goldberg, MD</strong><br /><i>Clinical Professor of Psychiatry</i><br />Department of Psychiatry<br />Icahn School of Medicine at Mount Sinai<br />New York, New York</p><p><strong>Roger McIntyre, MD, FRCPC</strong><br /><i>Professor of Psychiatry and Pharmacology</i><br />Department of Psychiatry/Pharmacology<br />University of Toronto<br /><i>Head</i>, Mood Disorders Psychopharmacology Unit<br />Department of Psychiatry<br />Toronto, Canada</p><p>This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.</p><p>For more programs in this series, visit:<br /><a href="https://bit.ly/3ft1rYI" target="_blank">https://bit.ly/3ft1rYI</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="28667070" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/0a176ff2-5883-4afb-be58-c4a5e88d5b98/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=0a176ff2-5883-4afb-be58-c4a5e88d5b98&amp;feed=K2gejSy4"/>
      <itunes:title>Symptom Management in Bipolar Depression: Realistic Expectations and Strategies for Improvement</itunes:title>
      <itunes:author>Joseph F. Goldberg MD, Roger McIntyre MD FRCPC</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/bb952e9c-9ce5-45a3-bbad-ca80e234e701/3000x3000/sy-bipolar-depression-podcast-icon-5.jpg?aid=rss_feed"/>
      <itunes:duration>00:29:50</itunes:duration>
      <itunes:summary>Joseph F. Goldberg, MD, and Roger McIntyre, MD, FRCPC, discuss strategies and expectations for symptom management in bipolar depression, including the value of measurement-based care in optimizing patient outcomes.</itunes:summary>
      <itunes:subtitle>Joseph F. Goldberg, MD, and Roger McIntyre, MD, FRCPC, discuss strategies and expectations for symptom management in bipolar depression, including the value of measurement-based care in optimizing patient outcomes.</itunes:subtitle>
      <itunes:keywords>comorbidities, depression, irritability, prescription, antipsychotic, agitation, mood diary, follow up, timeline, hypomania, mood disorder, psychiatry, cariprazine, side effects, cognition, lurasidone, anxiety, psychosis, mania, anhedonia, psychopharmacology, lithium, bipolar, patient education, symptoms, measurement-based care, patient relationship, akathisia, shared decision-making</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>18</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">3954579c-6dc4-4930-8996-53151caa9339</guid>
      <title>A Comprehensive Look at Tardive Dyskinesia Management</title>
      <description><![CDATA[<p>In this podcast episode, Robert O. Cotes, MD, and Jonathan M. Meyer, MD, discuss tardive dyskinesia from identification to follow-up and ongoing management. They provide valuable insights on pharmacologic options to both consider and avoid to optimize outcomes in patients with tardive dyskinesia, including a focus on clinical strategies for use of VMAT2 inhibitors.</p><p>Presenters:</p><p><strong>Robert O. Cotes, MD</strong><br /><i>Associate Professor</i><br />Department of Psychiatry and Behavioral Sciences<br />Emory University School of Medicine<br />Atlanta, Georgia</p><p><strong>Jonathan M. Meyer, MD</strong><br /><i>Voluntary Clinical Professor</i>, Department of Psychiatry<br />University of California, San Diego<br /><i>Psychopharmacology Consultant</i><br />Balboa Naval Medical Center First Episode Psychosis Program<br />State of Nevada Project ECHO First Episode Psychosis Program</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Fri, 28 Oct 2022 20:30:00 +0000</pubDate>
      <author>support@deceraclinical.com (Robert O. Cotes MD, Jonathan M. Meyer MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/managing-td-an-overview-kdHNlJzu</link>
      <content:encoded><![CDATA[<p>In this podcast episode, Robert O. Cotes, MD, and Jonathan M. Meyer, MD, discuss tardive dyskinesia from identification to follow-up and ongoing management. They provide valuable insights on pharmacologic options to both consider and avoid to optimize outcomes in patients with tardive dyskinesia, including a focus on clinical strategies for use of VMAT2 inhibitors.</p><p>Presenters:</p><p><strong>Robert O. Cotes, MD</strong><br /><i>Associate Professor</i><br />Department of Psychiatry and Behavioral Sciences<br />Emory University School of Medicine<br />Atlanta, Georgia</p><p><strong>Jonathan M. Meyer, MD</strong><br /><i>Voluntary Clinical Professor</i>, Department of Psychiatry<br />University of California, San Diego<br /><i>Psychopharmacology Consultant</i><br />Balboa Naval Medical Center First Episode Psychosis Program<br />State of Nevada Project ECHO First Episode Psychosis Program</p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="21831390" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/2087a0a9-4187-4b2c-ba22-714ce5c052c7/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=2087a0a9-4187-4b2c-ba22-714ce5c052c7&amp;feed=K2gejSy4"/>
      <itunes:title>A Comprehensive Look at Tardive Dyskinesia Management</itunes:title>
      <itunes:author>Robert O. Cotes MD, Jonathan M. Meyer MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/4131d070-81ff-4e87-980a-1ed1ed114456/3000x3000/pod474-sy-tardive-dyskinesia-podcast-teva-4.jpg?aid=rss_feed"/>
      <itunes:duration>00:22:37</itunes:duration>
      <itunes:summary>In this podcast episode, Robert O. Cotes, MD, and Jonathan M. Meyer, MD, discuss tardive dyskinesia management from identification to follow-up, with a focus on VMAT2 inhibitors as a pharmacologic management strategy.</itunes:summary>
      <itunes:subtitle>In this podcast episode, Robert O. Cotes, MD, and Jonathan M. Meyer, MD, discuss tardive dyskinesia management from identification to follow-up, with a focus on VMAT2 inhibitors as a pharmacologic management strategy.</itunes:subtitle>
      <itunes:keywords>tardive dyskinesia, clozapine, anticholinergics, deutetrabenazine, physician assistant, vmat2 inhibitors, psychiatry, healthcare provider, aims exam, psychiatrist, clinician, nurse, valbenazine, drug-induced movement disorder, amantadine, psychologist, nurse practitioner, pharmacist, antipsychotics</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>17</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">6aecf501-1cdb-42a6-bb41-20db02e12ed3</guid>
      <title>Pharmacologic Management Options for Patients With Tardive Dyskinesia</title>
      <description><![CDATA[<p>In this podcast episode, Diana O. Perkins, MD, MPH, and Rajiv Tandon, MD, provide a wealth of information on VMAT2 inhibitors and their use for tardive dyskinesia (TD) management. Their discussion includes information on VMAT2 inhibitor emergence in clinical practice, mechanism of action, adverse event profiles, insurance coverage, and strategies for initiation and titration. In addition to VMAT2 inhibitors, the experts touch on off-label options for TD management and their place in the TD management paradigm.</p><p>Presenters:</p><p>Diana O. Perkins, MD, MPH<br /><i>Professor, </i>Psychiatry<br />University of North Carolina at Chapel Hill<br />Chapel Hill, North Carolina</p><p>Rajiv Tandon, MD<br /><i>Emeritus Professor of Psychiatry</i><br />Department of Psychiatry<br />Western Michigan University Homer Stryker MD College of Medicine<br />Kalamazoo, Michigan</p><p>This content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences.</p><p>For more programs in this series, visit:<br /><a href="https://bit.ly/3yOL8f7" target="_blank"><strong>https://bit.ly/3yOL8f7</strong></a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Mon, 17 Oct 2022 20:30:00 +0000</pubDate>
      <author>support@deceraclinical.com (Diana Perkins MD MPH)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/td-management-options-rNT9rTIJ</link>
      <content:encoded><![CDATA[<p>In this podcast episode, Diana O. Perkins, MD, MPH, and Rajiv Tandon, MD, provide a wealth of information on VMAT2 inhibitors and their use for tardive dyskinesia (TD) management. Their discussion includes information on VMAT2 inhibitor emergence in clinical practice, mechanism of action, adverse event profiles, insurance coverage, and strategies for initiation and titration. In addition to VMAT2 inhibitors, the experts touch on off-label options for TD management and their place in the TD management paradigm.</p><p>Presenters:</p><p>Diana O. Perkins, MD, MPH<br /><i>Professor, </i>Psychiatry<br />University of North Carolina at Chapel Hill<br />Chapel Hill, North Carolina</p><p>Rajiv Tandon, MD<br /><i>Emeritus Professor of Psychiatry</i><br />Department of Psychiatry<br />Western Michigan University Homer Stryker MD College of Medicine<br />Kalamazoo, Michigan</p><p>This content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences.</p><p>For more programs in this series, visit:<br /><a href="https://bit.ly/3yOL8f7" target="_blank"><strong>https://bit.ly/3yOL8f7</strong></a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="34432216" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/5d5c3562-ffef-405a-97bd-f55c4131b03f/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=5d5c3562-ffef-405a-97bd-f55c4131b03f&amp;feed=K2gejSy4"/>
      <itunes:title>Pharmacologic Management Options for Patients With Tardive Dyskinesia</itunes:title>
      <itunes:author>Diana Perkins MD MPH</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/2e5234ff-73b5-430c-81f8-529e0b63a7bb/3000x3000/sy-tardive-dyskinesia-podcast-icon-3.jpg?aid=rss_feed"/>
      <itunes:duration>00:35:49</itunes:duration>
      <itunes:summary>Listen to Diana O. Perkins, MD, MPH, and Rajiv Tandon, MD, discuss the utility of VMAT2 inhibitors for tardive dyskinesia. The experts also touch on off-label and emerging options for tardive dyskinesia, giving healthcare professionals a wealth of information on pharmacologic management.</itunes:summary>
      <itunes:subtitle>Listen to Diana O. Perkins, MD, MPH, and Rajiv Tandon, MD, discuss the utility of VMAT2 inhibitors for tardive dyskinesia. The experts also touch on off-label and emerging options for tardive dyskinesia, giving healthcare professionals a wealth of information on pharmacologic management.</itunes:subtitle>
      <itunes:keywords>healthcare, tardive dyskinesia, neurotransmitter, deutetrabenazine, tetrabenazine, schizophrenia, antipsychotic, vmat2, dopamine, psychiatry, vesicular monoamine transport 2 inhibitor, valbenazine, reserpine</itunes:keywords>
      <itunes:explicit>true</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>13</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">65c01dfe-f94a-4f7b-992a-f426fb2682e1</guid>
      <title>Treatment Considerations Across the Bipolar Depression Spectrum</title>
      <description><![CDATA[<p>In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, share their thoughts on treatment strategies across the bipolar depression spectrum. They begin by talking about their stance on treating bipolar with comorbidities with a holistic vs stepwise approach and discuss what strategies they would consider for a patient not yet diagnosed with but who is at risk of developing bipolar depression. In addition, they discuss the concept of phase-specific treatment, considerations for medication-related adverse events, and the utility of adjunctive measures for managing bipolar depression. </p><p>Presenters:</p><p><strong>Greg W. Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p><strong>Vladimir Maletic MD</strong><br /><i>Clinical Professor</i><br />Department of Psychiatry<br />USC School of Medicine<br />Greenville, South Carolina</p><p>This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.</p><p>For more programs in this series, visit: <br /><a href="https://bit.ly/3TClDqb" target="_blank">https://bit.ly/3TClDqb</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Thu, 6 Oct 2022 20:00:00 +0000</pubDate>
      <author>support@deceraclinical.com (Greg W Mattingly MD, Vladimir Maletic MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/treatment-considerations-across-the-bipolar-depression-spectrum-WZt46Va9</link>
      <content:encoded><![CDATA[<p>In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, share their thoughts on treatment strategies across the bipolar depression spectrum. They begin by talking about their stance on treating bipolar with comorbidities with a holistic vs stepwise approach and discuss what strategies they would consider for a patient not yet diagnosed with but who is at risk of developing bipolar depression. In addition, they discuss the concept of phase-specific treatment, considerations for medication-related adverse events, and the utility of adjunctive measures for managing bipolar depression. </p><p>Presenters:</p><p><strong>Greg W. Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p><strong>Vladimir Maletic MD</strong><br /><i>Clinical Professor</i><br />Department of Psychiatry<br />USC School of Medicine<br />Greenville, South Carolina</p><p>This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.</p><p>For more programs in this series, visit: <br /><a href="https://bit.ly/3TClDqb" target="_blank">https://bit.ly/3TClDqb</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="24373783" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/6430abad-2c97-481b-8dba-2dd5d94897e7/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=6430abad-2c97-481b-8dba-2dd5d94897e7&amp;feed=K2gejSy4"/>
      <itunes:title>Treatment Considerations Across the Bipolar Depression Spectrum</itunes:title>
      <itunes:author>Greg W Mattingly MD, Vladimir Maletic MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/6f402e9a-eac4-455d-8334-2996f9c0edae/75c2b5d9-a774-4c8f-9cbb-7eae653d5966/3000x3000/pod466-bipolar-spectrum-treatment-podcast-04.jpg?aid=rss_feed"/>
      <itunes:duration>00:25:22</itunes:duration>
      <itunes:summary>Listen as 2 experts in psychiatry discuss treatment strategies across the spectrum of bipolar depression—including in patients with comorbidities and patients at risk of developing bipolar depression—as well as their thoughts regarding phase-specific vs holistic treatment approaches.</itunes:summary>
      <itunes:subtitle>Listen as 2 experts in psychiatry discuss treatment strategies across the spectrum of bipolar depression—including in patients with comorbidities and patients at risk of developing bipolar depression—as well as their thoughts regarding phase-specific vs holistic treatment approaches.</itunes:subtitle>
      <itunes:keywords>healthcare, suicide, adhd, dsm-5, manic episode, bipolar spectrum, physician assistant, bipolar disorder, mental health, unipolar depression, mood stabilizer, psychotherapy, holistic, hypomania, psychiatry, second-generation antipsychotic, anxiety, mania, clinician, mixed features, pediatric, stimulants, first-generation antipsychotic, bipolar depression, resilience, nurse practitioner, atypical antipsychotic, physician, mood disorders, antipsychotics</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>16</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">e8ba9a94-0f67-4e3a-81a3-6cb99fe47b70</guid>
      <title>Patient Interview: Living With Tardive Dyskinesia</title>
      <description><![CDATA[<p>In this podcast episode on tardive dyskinesia (TD), Joseph P. McEvoy, MD, interviews Leslie, a patient who was diagnosed with TD 10 years ago. She describes her journey to an accurate diagnosis, the impact that TD has on her daily life, and her advice for patients and providers affected by TD.</p><p>Presenters:</p><p><strong>Joseph P. McEvoy MD</strong><br /><i>Professor</i><br />Psychiatry and Health Behavior<br /><i>Psychiatrist</i><br />Augusta University<br />Augusta, Georgia</p><p><strong>Leslie</strong></p><p>This content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences, Inc.</p><p>For more programs in this series, visit:<br /><a href="https://bit.ly/3dUCVi6" target="_blank">https://bit.ly/3dUCVi6</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Wed, 28 Sep 2022 16:00:00 +0000</pubDate>
      <author>support@deceraclinical.com (Joseph McEvoy MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/living-with-td-WCXn2o79</link>
      <content:encoded><![CDATA[<p>In this podcast episode on tardive dyskinesia (TD), Joseph P. McEvoy, MD, interviews Leslie, a patient who was diagnosed with TD 10 years ago. She describes her journey to an accurate diagnosis, the impact that TD has on her daily life, and her advice for patients and providers affected by TD.</p><p>Presenters:</p><p><strong>Joseph P. McEvoy MD</strong><br /><i>Professor</i><br />Psychiatry and Health Behavior<br /><i>Psychiatrist</i><br />Augusta University<br />Augusta, Georgia</p><p><strong>Leslie</strong></p><p>This content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences, Inc.</p><p>For more programs in this series, visit:<br /><a href="https://bit.ly/3dUCVi6" target="_blank">https://bit.ly/3dUCVi6</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="16241494" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/3173364f-80df-4489-b4a5-b46e8c080240/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=3173364f-80df-4489-b4a5-b46e8c080240&amp;feed=K2gejSy4"/>
      <itunes:title>Patient Interview: Living With Tardive Dyskinesia</itunes:title>
      <itunes:author>Joseph McEvoy MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/6106e615-e086-491d-88e5-31a5b5a617e6/3000x3000/sy-tardive-dyskinesia-podcast-icon-2.jpg?aid=rss_feed"/>
      <itunes:duration>00:16:54</itunes:duration>
      <itunes:summary>Listen to Leslie, a patient with TD for the past 10 years, describe her experience with the disease from diagnosis to current impact on her daily life.</itunes:summary>
      <itunes:subtitle>Listen to Leslie, a patient with TD for the past 10 years, describe her experience with the disease from diagnosis to current impact on her daily life.</itunes:subtitle>
      <itunes:keywords>tardive dyskinesia, diagnosis, psychiatric, healthcare provider, dyskinesia, neurology, psychiatrist, movement disorders, quality of life, patient perspective, drug-induced movement disorder, neurologist, antipsychotics</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>12</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">0eb2825d-dc0e-460a-b9d0-ab2786beaf9c</guid>
      <title>Diagnosis Detective: Accurately Identifying Bipolar Depression</title>
      <description><![CDATA[<p>In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, have a conversation about the complexities of accurately diagnosing bipolar depression. Bipolar depression can be difficult to differentiate from other psychiatric conditions, such as unipolar depression, depression with mixed features, ADHD, PTSD, and anxiety. This differential is made more challenging in that patients with bipolar depression often have psychiatric comorbidities with overlapping symptomology. Listen as the 2 psychiatrists share their insights on how to act as detectives and weed through clues from current symptoms, past symptoms, and family history to reach an accurate diagnosis. </p><p>Presenters:</p><p><strong>Greg W. Mattingly, MD</strong><br /><i>Associate Clinical Professor</i> Psychiatry<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p><strong>Vladimir Maletic MD</strong><br /><i>Clinical Professor</i><br />Department of Psychiatry<br />USC School of Medicine<br />Greenville, South Carolina</p><p>This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.</p><p>For more programs in this series, visit: <br /><a href="https://bit.ly/3TClDqb" target="_blank">https://bit.ly/3TClDqb</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Fri, 2 Sep 2022 17:05:00 +0000</pubDate>
      <author>support@deceraclinical.com (Vladimir Maletic MD, Greg W Mattingly MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/diagnosis-detective-accurately-identifying-bipolar-depression-8VFv1s_i</link>
      <content:encoded><![CDATA[<p>In this episode, Greg W. Mattingly, MD, and Vladimir Maletic, MD, have a conversation about the complexities of accurately diagnosing bipolar depression. Bipolar depression can be difficult to differentiate from other psychiatric conditions, such as unipolar depression, depression with mixed features, ADHD, PTSD, and anxiety. This differential is made more challenging in that patients with bipolar depression often have psychiatric comorbidities with overlapping symptomology. Listen as the 2 psychiatrists share their insights on how to act as detectives and weed through clues from current symptoms, past symptoms, and family history to reach an accurate diagnosis. </p><p>Presenters:</p><p><strong>Greg W. Mattingly, MD</strong><br /><i>Associate Clinical Professor</i> Psychiatry<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p><strong>Vladimir Maletic MD</strong><br /><i>Clinical Professor</i><br />Department of Psychiatry<br />USC School of Medicine<br />Greenville, South Carolina</p><p>This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.</p><p>For more programs in this series, visit: <br /><a href="https://bit.ly/3TClDqb" target="_blank">https://bit.ly/3TClDqb</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="28642055" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/baee2866-704f-49a6-85b9-216b73e16416/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=baee2866-704f-49a6-85b9-216b73e16416&amp;feed=K2gejSy4"/>
      <itunes:title>Diagnosis Detective: Accurately Identifying Bipolar Depression</itunes:title>
      <itunes:author>Vladimir Maletic MD, Greg W Mattingly MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/6f402e9a-eac4-455d-8334-2996f9c0edae/1040124a-4eb7-4f92-bb46-60572e00db23/3000x3000/pod465-bipolar-depression-additional-podcast-03.jpg?aid=rss_feed"/>
      <itunes:duration>00:29:49</itunes:duration>
      <itunes:summary>Listen as 2 experts in psychiatry provide insight on how to navigate the many differential diagnoses and comorbidities associated with bipolar depression.</itunes:summary>
      <itunes:subtitle>Listen as 2 experts in psychiatry provide insight on how to navigate the many differential diagnoses and comorbidities associated with bipolar depression.</itunes:subtitle>
      <itunes:keywords>healthcare, adhd, trauma, dsm-5, manic episode, bipolar spectrum, physician assistant, bipolar disorder, mental health, unipolar depression, major depressive disorder, hypomania, psychiatry, anxiety, mania, clinician, mixed features, ptsd, bipolar depression, nurse practitioner, physician, mood disorders, mdd, differential diagnosis</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>15</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">c71928d8-1eaf-46fa-b896-03b6007ed516</guid>
      <title>Answering Your Questions About Bipolar Depression</title>
      <description><![CDATA[<p>Get answers to the questions that you and your colleagues have asked! In this episode, Charles DeBattista, MD, provides answers to audience questions that were submitted at 2 recent Psychiatry Update meetings. His thoughtful responses cover your questions on differential diagnosis, initiating pharmacotherapy, medication management, and more. Moderators Amber Hoberg, PMHNP, and Greg W. Mattingly, MD, provide complementary commentary throughout the Q&A session, adding interprofessional perspective to the activity.</p><p>Presenters:</p><p><strong>Charles DeBattista, DMH, MD</strong><br /><i>Chief</i><br />Depression Research Clinic<br /><i>Director</i><br />Medical Student Education in Psychiatry<br /><i>Professor of Psychiatry and Behavioral Sciences</i><br />Stanford University School of Medicine<br />Stanford, California</p><p><strong>Amber Hoberg, PMHNP</strong><br /><i>Nurse Practitioner</i><br />MorningStar Family Medicine<br />Floresville, Texas</p><p><strong>Greg W. Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p>This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.</p><p>For more programs in this series, visit:<br /><a href="https://bit.ly/3cX8eby" target="_blank">https://bit.ly/3cX8eby</a></p><p>Register for our Psychiatry Update 2022 series. This program is free and will offer up to 5 CME/CE credits. </p><ul><li>For physicians (MD, DO), psychiatry specialist NPs and PAs, pharmacists, social workers, and psychologists, register at:<br /><a href="https://bit.ly/3Q1WLWR" target="_blank">https://bit.ly/3Q1WLWR</a></li><li>For NPs and PAs in primary care/other specialties, register at:<br /><a href="https://bit.ly/3Jf54Ma" target="_blank">https://bit.ly/3Jf54Ma</a></li></ul><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Mon, 1 Aug 2022 20:00:00 +0000</pubDate>
      <author>support@deceraclinical.com (Charles DeBattista DMH MD, Amber Hoberg PMHNP, Greg W Mattingly MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/answering-your-questions-about-bipolar-depression-sD7szi_e</link>
      <content:encoded><![CDATA[<p>Get answers to the questions that you and your colleagues have asked! In this episode, Charles DeBattista, MD, provides answers to audience questions that were submitted at 2 recent Psychiatry Update meetings. His thoughtful responses cover your questions on differential diagnosis, initiating pharmacotherapy, medication management, and more. Moderators Amber Hoberg, PMHNP, and Greg W. Mattingly, MD, provide complementary commentary throughout the Q&A session, adding interprofessional perspective to the activity.</p><p>Presenters:</p><p><strong>Charles DeBattista, DMH, MD</strong><br /><i>Chief</i><br />Depression Research Clinic<br /><i>Director</i><br />Medical Student Education in Psychiatry<br /><i>Professor of Psychiatry and Behavioral Sciences</i><br />Stanford University School of Medicine<br />Stanford, California</p><p><strong>Amber Hoberg, PMHNP</strong><br /><i>Nurse Practitioner</i><br />MorningStar Family Medicine<br />Floresville, Texas</p><p><strong>Greg W. Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p>This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.</p><p>For more programs in this series, visit:<br /><a href="https://bit.ly/3cX8eby" target="_blank">https://bit.ly/3cX8eby</a></p><p>Register for our Psychiatry Update 2022 series. This program is free and will offer up to 5 CME/CE credits. </p><ul><li>For physicians (MD, DO), psychiatry specialist NPs and PAs, pharmacists, social workers, and psychologists, register at:<br /><a href="https://bit.ly/3Q1WLWR" target="_blank">https://bit.ly/3Q1WLWR</a></li><li>For NPs and PAs in primary care/other specialties, register at:<br /><a href="https://bit.ly/3Jf54Ma" target="_blank">https://bit.ly/3Jf54Ma</a></li></ul><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="15727799" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/cebc997b-257e-4ef1-8b8b-67e3f95eae34/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=cebc997b-257e-4ef1-8b8b-67e3f95eae34&amp;feed=K2gejSy4"/>
      <itunes:title>Answering Your Questions About Bipolar Depression</itunes:title>
      <itunes:author>Charles DeBattista DMH MD, Amber Hoberg PMHNP, Greg W Mattingly MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/6f402e9a-eac4-455d-8334-2996f9c0edae/7e274ec9-747c-4024-ae99-74bb79d044ea/3000x3000/cliniciansxchange-neu-podcast-bipolar-depression-faq-3000x3000.jpg?aid=rss_feed"/>
      <itunes:duration>00:16:18</itunes:duration>
      <itunes:summary>Following 2 recent Psychiatry Update meetings, Dr Charles DeBattista answers your most asked questions on bipolar depression with mixed features. </itunes:summary>
      <itunes:subtitle>Following 2 recent Psychiatry Update meetings, Dr Charles DeBattista answers your most asked questions on bipolar depression with mixed features. </itunes:subtitle>
      <itunes:keywords>healthcare, psychiatry update, dsm-5, manic episode, bipolar spectrum, physician assistant, bipolar disorder, mental health, depression, irritability, unipolar depression, hypomania, psychiatry, clinical care options, second-generation antipsychotic, mania, clinician, mixed features, benzodiazepines, first-generation antipsychotic, nurse practitioner, physician, mood disorders, antipsychotics, differential diagnosis</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>14</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">a94f2eb9-f268-450a-aa77-6b1c85b3da2f</guid>
      <title>How Can We Screen for and Identify Tardive Dyskinesia?</title>
      <description><![CDATA[<p>In this first of 6 podcast episodes on tardive dyskinesia (TD), Drs Greg W. Mattingly and Jonathan M. Meyer have a discussion on identifying TD in clinical practice—including how to effectively screen patients during telehealth appointments. They cover who should be screened and how often, informal vs formal screening, and the valuable insight that family/caregiver reports can provide in the identification process. Additional conversation sheds light on differentiating TD from other movement disorders, including tics and tremors, and the role of primary care and other specialty providers in helping to identify TD. The experts round out the podcast with a focus on the impact of TD on both patient and caregiver quality of life—even mild TD can have an enormous influence over emotional, social, and mental well-being—bringing home the point that screening for and identifying TD early on is very important for patient outcomes.</p><p>Presenters:</p><p><strong>Greg W. Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p><strong>Jonathan M. Meyer, MD</strong><br /><i>Voluntary Clinical Professor</i><br />Department of Psychiatry<br />University of California, San Diego<br /><i>Psychopharmacology Consultant</i><br />Balboa Naval Medical Center First Episode Psychosis Program<br />State of Nevada Project ECHO First Episode Psychosis Program</p><p>This content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences, Inc.</p><p>For more programs in this series, visit: <br /><a href="https://bit.ly/3AhRXau" target="_blank">https://bit.ly/3AhRXau</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Mon, 11 Jul 2022 17:00:00 +0000</pubDate>
      <author>support@deceraclinical.com (Greg Mattingly MD, Jonathan Meyer MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/td-screening-UEVHXEsq</link>
      <content:encoded><![CDATA[<p>In this first of 6 podcast episodes on tardive dyskinesia (TD), Drs Greg W. Mattingly and Jonathan M. Meyer have a discussion on identifying TD in clinical practice—including how to effectively screen patients during telehealth appointments. They cover who should be screened and how often, informal vs formal screening, and the valuable insight that family/caregiver reports can provide in the identification process. Additional conversation sheds light on differentiating TD from other movement disorders, including tics and tremors, and the role of primary care and other specialty providers in helping to identify TD. The experts round out the podcast with a focus on the impact of TD on both patient and caregiver quality of life—even mild TD can have an enormous influence over emotional, social, and mental well-being—bringing home the point that screening for and identifying TD early on is very important for patient outcomes.</p><p>Presenters:</p><p><strong>Greg W. Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p><strong>Jonathan M. Meyer, MD</strong><br /><i>Voluntary Clinical Professor</i><br />Department of Psychiatry<br />University of California, San Diego<br /><i>Psychopharmacology Consultant</i><br />Balboa Naval Medical Center First Episode Psychosis Program<br />State of Nevada Project ECHO First Episode Psychosis Program</p><p>This content is based on a CE/CME program supported by independent educational grants from Neurocrine Biosciences, Inc.</p><p>For more programs in this series, visit: <br /><a href="https://bit.ly/3AhRXau" target="_blank">https://bit.ly/3AhRXau</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="22292318" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/c238e777-79a9-4c0f-9ab0-051dcd87362d/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=c238e777-79a9-4c0f-9ab0-051dcd87362d&amp;feed=K2gejSy4"/>
      <itunes:title>How Can We Screen for and Identify Tardive Dyskinesia?</itunes:title>
      <itunes:author>Greg Mattingly MD, Jonathan Meyer MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/34512a8a-2c39-4c95-80f8-10c1e96d4b97/3000x3000/sy-tardive-dyskinesia-podcast-icon-1.jpg?aid=rss_feed"/>
      <itunes:duration>00:23:11</itunes:duration>
      <itunes:summary>Listen to 2 thought leaders in the psychiatry field discuss the importance of screening for tardive dyskinesia in patients receiving antipsychotics, including clinical pearls for identification in various clinical settings.</itunes:summary>
      <itunes:subtitle>Listen to 2 thought leaders in the psychiatry field discuss the importance of screening for tardive dyskinesia in patients receiving antipsychotics, including clinical pearls for identification in various clinical settings.</itunes:subtitle>
      <itunes:keywords>activation parameter, telehealth, screening, tardive dyskinesia, caregiver, dsm-5, physician associate, collaborative care, schizophrenia, drug-induced, abnormal movement, motor function, physician assistant, healthcare providers, parkinsonism, psychiatric, extrapyramidal symptoms, risk factors, dyskinesia, aims exam, movement disorders, clinician, nurse, tremor, doctor, nurse practitioner, physician, tics, antipsychotics</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>10</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">eb753c59-dfe6-4c6c-9bab-5a69cd1b7db6</guid>
      <title>A Comprehensive Overview of the Bipolar Spectrum</title>
      <description><![CDATA[<p>In this episode, Drs Greg W. Mattingly and Charles DeBattista have a conversation about the history and features of the bipolar spectrum. Because patients can present in mixed vignettes, diagnosis of bipolar depression can be challenging. The experts offer insight on when to hold a suspicion for bipolar depression, as well as common presentations they have seen over their years in clinical practice. The conversation then progresses to potential “triggers” of bipolar depression and culminates with a discussion of the current treatment paradigm for patients with bipolar depression: first- or second-generation antipsychotics. </p><p>Presenters:</p><p><strong>Greg W. Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p><strong>Charles DeBattista, DMH, MD</strong><br /><i>Chief</i><br />Depression Research Clinic<br /><i>Director</i><br />Medical Student Education in Psychiatry<br /><i>Professor of Psychiatry and Behavioral Sciences</i><br />Stanford University School of Medicine<br />Stanford, California</p><p>This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.</p><p>For more programs in this series, visit: <br /><a href="bit.ly/3bPCiVH" target="_blank">https://bit.ly/3bPCiVH</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Thu, 7 Jul 2022 20:45:00 +0000</pubDate>
      <author>support@deceraclinical.com (Greg W Mattingly MD, Charles DeBattista DMH MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/bipolar-spectrum-overview-AmuexnDu</link>
      <content:encoded><![CDATA[<p>In this episode, Drs Greg W. Mattingly and Charles DeBattista have a conversation about the history and features of the bipolar spectrum. Because patients can present in mixed vignettes, diagnosis of bipolar depression can be challenging. The experts offer insight on when to hold a suspicion for bipolar depression, as well as common presentations they have seen over their years in clinical practice. The conversation then progresses to potential “triggers” of bipolar depression and culminates with a discussion of the current treatment paradigm for patients with bipolar depression: first- or second-generation antipsychotics. </p><p>Presenters:</p><p><strong>Greg W. Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p><strong>Charles DeBattista, DMH, MD</strong><br /><i>Chief</i><br />Depression Research Clinic<br /><i>Director</i><br />Medical Student Education in Psychiatry<br /><i>Professor of Psychiatry and Behavioral Sciences</i><br />Stanford University School of Medicine<br />Stanford, California</p><p>This content is based on a CE/CME program supported by independent educational grants from AbbVie and Intra-Cellular Therapies, Inc.</p><p>For more programs in this series, visit: <br /><a href="bit.ly/3bPCiVH" target="_blank">https://bit.ly/3bPCiVH</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="18544222" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/2b60bf81-1a11-4efa-a888-bfe15497ae89/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=2b60bf81-1a11-4efa-a888-bfe15497ae89&amp;feed=K2gejSy4"/>
      <itunes:title>A Comprehensive Overview of the Bipolar Spectrum</itunes:title>
      <itunes:author>Greg W Mattingly MD, Charles DeBattista DMH MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/6f402e9a-eac4-455d-8334-2996f9c0edae/5d7a7864-0b05-4166-9c67-662d05ac2cb3/3000x3000/sy-bipolar-depression-podcast-icon-1.jpg?aid=rss_feed"/>
      <itunes:duration>00:19:16</itunes:duration>
      <itunes:summary>Listen as 2 experts in psychiatry provide an overview of the bipolar spectrum, including identifying bipolar depression with mixed presentations and various treatment strategies. </itunes:summary>
      <itunes:subtitle>Listen as 2 experts in psychiatry provide an overview of the bipolar spectrum, including identifying bipolar depression with mixed presentations and various treatment strategies. </itunes:subtitle>
      <itunes:keywords>healthcare, dsm-5, manic episode, bipolar spectrum, physician assistant, bipolar disorder, mental health, unipolar depression, hypomania, psychiatry, second-generation antipsychotic, mania, clinician, mixed features, first-generation antipsychotic, bipolar depression, nurse practitioner, physician, mood disorders, antipsychotics, differential diagnosis</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>11</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">5940bc31-21bf-4024-b915-b5209ee7615a</guid>
      <title>The Functional and Social Impact of TD on the Lives of Patients</title>
      <description><![CDATA[<p>In this episode, Diana Perkins, MD, MPH, and Martha Sajatovic, MD, discuss the impact of tardive dyskinesia on social and functional domains and the benefits of proper assessment and treatment of tardive dyskinesia in improving patient quality of life in these areas.</p><p>Presenters:</p><p><strong>Diana Perkins, MD, MPH</strong><br /><i>Professor of Psychiatry </i><br />University of North Carolina School of Medicine<br />Chapel Hill, North Carolina </p><p><strong>Martha Sajatovic, MD</strong><br /><i>Professor of</i> <i>Psychiatry and Neurology</i><br />Departments of Psychiatry and Neurology<br />Case Western Reserve University School of Medicine<br />Cleveland, Ohio</p><p>Link to full program:<br /><a href="https://bit.ly/3GkJmUS" target="_blank">https://bit.ly/3GkJmUS</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 11 Jan 2022 18:30:00 +0000</pubDate>
      <author>support@deceraclinical.com (Diana Perkins MD MPH, Martha Sajatovic MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/episode-title-the-functional-and-social-impact-of-td-on-the-lives-of-patients-qPPnYRWu</link>
      <content:encoded><![CDATA[<p>In this episode, Diana Perkins, MD, MPH, and Martha Sajatovic, MD, discuss the impact of tardive dyskinesia on social and functional domains and the benefits of proper assessment and treatment of tardive dyskinesia in improving patient quality of life in these areas.</p><p>Presenters:</p><p><strong>Diana Perkins, MD, MPH</strong><br /><i>Professor of Psychiatry </i><br />University of North Carolina School of Medicine<br />Chapel Hill, North Carolina </p><p><strong>Martha Sajatovic, MD</strong><br /><i>Professor of</i> <i>Psychiatry and Neurology</i><br />Departments of Psychiatry and Neurology<br />Case Western Reserve University School of Medicine<br />Cleveland, Ohio</p><p>Link to full program:<br /><a href="https://bit.ly/3GkJmUS" target="_blank">https://bit.ly/3GkJmUS</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="26276928" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/8c75ae30-c29c-4e92-baf8-54c7b7fd3f1a/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=8c75ae30-c29c-4e92-baf8-54c7b7fd3f1a&amp;feed=K2gejSy4"/>
      <itunes:title>The Functional and Social Impact of TD on the Lives of Patients</itunes:title>
      <itunes:author>Diana Perkins MD MPH, Martha Sajatovic MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/3ebf6bac-44e1-4c51-b67d-1081dbf65e99/6408dce4-601a-43f0-a759-a513292bd88e/3000x3000/sy-tardive-dyskinesia-podcasticon-6.jpg?aid=rss_feed"/>
      <itunes:duration>00:27:13</itunes:duration>
      <itunes:summary>Diana Perkins, MD, MPH, and Martha Sajatovic, MD, discuss the functional and social impact of tardive dyskinesia on the lives of patients. 
</itunes:summary>
      <itunes:subtitle>Diana Perkins, MD, MPH, and Martha Sajatovic, MD, discuss the functional and social impact of tardive dyskinesia on the lives of patients. 
</itunes:subtitle>
      <itunes:keywords>tardive dyskinesia, psychotherapies, psychiatric, neuromuscular disorders, dyskinesia, aims exam, movement disorders, tremor</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>9</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">ad201562-8979-4c8f-9346-303abfac0d48</guid>
      <title>Evidence-Based Approaches to Choosing the Right Treatment for Bipolar Depression</title>
      <description><![CDATA[<p>In this episode, Roger McIntyre, MD, FRCPC, and Sanjay Mathew, MD, discuss choosing the right treatment in bipolar depression. They review patient assessment and differential diagnosis for bipolar depression, describe various screening tools, examine evidence-based pharmacotherapies, consider the role of adjunctive antidepressants, neuromodulation, light therapy, and psychological treatments, and explore future directions in bipolar depression treatment.  </p><p>Presenters:</p><p><strong>Sanjay J. Mathew, MD</strong><br /><i>Professor and Vice Chair for Research</i><br />Psychiatry and Behavioral Sciences<br />Baylor College of Medicine<br />Houston, Texas</p><p><strong>Roger McIntyre, MD, FRCPC</strong><br /><i>Professor of Psychiatry and Pharmacology</i><br />Department of Psychiatry/Pharmacology<br />University of Toronto<br /><i>Head</i>, Mood Disorders Psychopharmacology Unit<br />Department of Psychiatry<br />Toronto, Canada</p><p>Link to full program:<br /><a href="https://bit.ly/3syJzh2" target="_blank">https://bit.ly/3syJzh2</a></p><p> </p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 30 Nov 2021 17:00:00 +0000</pubDate>
      <author>support@deceraclinical.com (Sanjay J Mathew MD, Roger McIntyre MD FRCPC)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/evidence-based-approaches-to-choosing-the-right-treatment-for-bipolar-depression-YibBmT9O</link>
      <content:encoded><![CDATA[<p>In this episode, Roger McIntyre, MD, FRCPC, and Sanjay Mathew, MD, discuss choosing the right treatment in bipolar depression. They review patient assessment and differential diagnosis for bipolar depression, describe various screening tools, examine evidence-based pharmacotherapies, consider the role of adjunctive antidepressants, neuromodulation, light therapy, and psychological treatments, and explore future directions in bipolar depression treatment.  </p><p>Presenters:</p><p><strong>Sanjay J. Mathew, MD</strong><br /><i>Professor and Vice Chair for Research</i><br />Psychiatry and Behavioral Sciences<br />Baylor College of Medicine<br />Houston, Texas</p><p><strong>Roger McIntyre, MD, FRCPC</strong><br /><i>Professor of Psychiatry and Pharmacology</i><br />Department of Psychiatry/Pharmacology<br />University of Toronto<br /><i>Head</i>, Mood Disorders Psychopharmacology Unit<br />Department of Psychiatry<br />Toronto, Canada</p><p>Link to full program:<br /><a href="https://bit.ly/3syJzh2" target="_blank">https://bit.ly/3syJzh2</a></p><p> </p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="29198842" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/b2a26baa-6d1d-4032-945a-87c97ecc7a24/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=b2a26baa-6d1d-4032-945a-87c97ecc7a24&amp;feed=K2gejSy4"/>
      <itunes:title>Evidence-Based Approaches to Choosing the Right Treatment for Bipolar Depression</itunes:title>
      <itunes:author>Sanjay J Mathew MD, Roger McIntyre MD FRCPC</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/3ebf6bac-44e1-4c51-b67d-1081dbf65e99/b36ebfca-d35c-4008-9de4-883c35642b9b/3000x3000/sy-bipolar-depression-podcasticon-treatment.jpg?aid=rss_feed"/>
      <itunes:duration>00:30:21</itunes:duration>
      <itunes:summary>Roger McIntyre, MD, FRCPC, and Sanjay J. Mathew, MD, discuss evidence-based approaches to choosing the right treatment for bipolar depression. </itunes:summary>
      <itunes:subtitle>Roger McIntyre, MD, FRCPC, and Sanjay J. Mathew, MD, discuss evidence-based approaches to choosing the right treatment for bipolar depression. </itunes:subtitle>
      <itunes:keywords>psychotherapies, bipolar ii, bipolar disorder, depression, bipolar i, psychiatric, psychiatry, neuroscience, mania, bipolar depression, mood disorders, mdd</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>8</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">d311574d-d053-472c-b5a7-abba135c59e8</guid>
      <title>Multidisciplinary Approach to Evaluation and Treatment of Tardive Dyskinesia</title>
      <description><![CDATA[<p>In this episode, Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh, discuss who PCPs should screen for TD, adverse effects PCPs should put on their radar screen when monitoring patients on antipsychotics, how TD is different from parkinsonism, the use of anticholinergics, and which patients have an increased risk for TD when on antipsychotics.  </p><p>Presenters:</p><p><strong>Greg Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry, Psychopharmacology<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p><strong>W. Clay Jackson, MD, DipTh</strong>  <br /><i>Assistant Professor of Clinical Family Medicine & Psychiatry</i><br />College of Medicine<br />University of Tennessee<br /><i>Director</i><br />Palliative Care<br />West Cancer Center<br />Memphis, Tennessee</p><p>Link to full program:<br /><a href="https://bit.ly/2RM8hfM" target="_blank">https://bit.ly/2RM8hfM</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 16 Nov 2021 19:20:00 +0000</pubDate>
      <author>support@deceraclinical.com (Greg Mattingly MD, W Clay Jackson MD DipTh)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/multidisciplinary-approach-to-evaluation-and-treatment-of-tardive-dyskinesia-5_1b2hc8</link>
      <content:encoded><![CDATA[<p>In this episode, Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh, discuss who PCPs should screen for TD, adverse effects PCPs should put on their radar screen when monitoring patients on antipsychotics, how TD is different from parkinsonism, the use of anticholinergics, and which patients have an increased risk for TD when on antipsychotics.  </p><p>Presenters:</p><p><strong>Greg Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry, Psychopharmacology<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p><strong>W. Clay Jackson, MD, DipTh</strong>  <br /><i>Assistant Professor of Clinical Family Medicine & Psychiatry</i><br />College of Medicine<br />University of Tennessee<br /><i>Director</i><br />Palliative Care<br />West Cancer Center<br />Memphis, Tennessee</p><p>Link to full program:<br /><a href="https://bit.ly/2RM8hfM" target="_blank">https://bit.ly/2RM8hfM</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="25301271" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/39aee40b-7454-420e-841a-60ad9ceaac9c/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=39aee40b-7454-420e-841a-60ad9ceaac9c&amp;feed=K2gejSy4"/>
      <itunes:title>Multidisciplinary Approach to Evaluation and Treatment of Tardive Dyskinesia</itunes:title>
      <itunes:author>Greg Mattingly MD, W Clay Jackson MD DipTh</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/3ebf6bac-44e1-4c51-b67d-1081dbf65e99/85943e68-3abc-4df4-9956-740def53bfa3/3000x3000/sy-tardive-dyskinesia-podcasticon-5.jpg?aid=rss_feed"/>
      <itunes:duration>00:26:17</itunes:duration>
      <itunes:summary>Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh, discuss a multidisciplinary approach to the evaluation and treatment of patients with tardive dyskinesia. </itunes:summary>
      <itunes:subtitle>Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh, discuss a multidisciplinary approach to the evaluation and treatment of patients with tardive dyskinesia. </itunes:subtitle>
      <itunes:keywords>tardive dyskinesia, psychotherapies, telepsychiatry, psychiatric, dyskinesia, aims exam, primary care, telepsych, antipsychotics</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>7</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">ea271b8d-8342-4dcc-90d4-ef8c7a7e3929</guid>
      <title>What Is the Role for Antidepressants in Bipolar Disorder?</title>
      <description><![CDATA[<p>In this episode, Joseph Goldberg, MD, and Greg Mattingly, MD, discuss the role of antidepressants in bipolar disorder. They review use of newer antidepressants (eg, vortioxetine, vilazodone) for bipolar depression despite lack of large, formal studies for that indication, the safety/efficacy of antidepressants for bipolar II vs bipolar I, antidepressant monotherapy in bipolar II depression, ketamine/esketamine for bipolar depression, and discuss the role for an antidepressant for bipolar depression in the absence of mixed features.  </p><p>Podcast from Clinical Care Options (CCO) with Joseph Goldberg, MD, and Greg Mattingly, MD, on the role of antidepressants in bipolar disorder.</p><p>Presenters:</p><p><strong>Joseph Goldberg, MD</strong><br /><i>Clinical Professor of Psychiatry</i><br />Department of Psychiatry<br />Icahn School of Medicine at Mount Sinai<br />New York, New York</p><p><strong>Greg Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry, Psychopharmacology<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri  </p><p>Link to full program:<br /><a href="https://bit.ly/3syJzh2" target="_blank">https://bit.ly/3syJzh2</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 5 Oct 2021 20:00:00 +0000</pubDate>
      <author>support@deceraclinical.com (Joseph Goldberg MD, Greg Mattingly MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/what-is-the-role-for-antidepressants-in-bipolar-disorder-gU5PyNkc</link>
      <content:encoded><![CDATA[<p>In this episode, Joseph Goldberg, MD, and Greg Mattingly, MD, discuss the role of antidepressants in bipolar disorder. They review use of newer antidepressants (eg, vortioxetine, vilazodone) for bipolar depression despite lack of large, formal studies for that indication, the safety/efficacy of antidepressants for bipolar II vs bipolar I, antidepressant monotherapy in bipolar II depression, ketamine/esketamine for bipolar depression, and discuss the role for an antidepressant for bipolar depression in the absence of mixed features.  </p><p>Podcast from Clinical Care Options (CCO) with Joseph Goldberg, MD, and Greg Mattingly, MD, on the role of antidepressants in bipolar disorder.</p><p>Presenters:</p><p><strong>Joseph Goldberg, MD</strong><br /><i>Clinical Professor of Psychiatry</i><br />Department of Psychiatry<br />Icahn School of Medicine at Mount Sinai<br />New York, New York</p><p><strong>Greg Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry, Psychopharmacology<br />Washington University School of Medicine<br />St Louis, Missouri<br /><i>President</i><br />St Charles Psychiatry Associates<br />St Charles, Missouri  </p><p>Link to full program:<br /><a href="https://bit.ly/3syJzh2" target="_blank">https://bit.ly/3syJzh2</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="33484255" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/a6af9e77-2627-49c2-ae3d-900540ec46f8/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=a6af9e77-2627-49c2-ae3d-900540ec46f8&amp;feed=K2gejSy4"/>
      <itunes:title>What Is the Role for Antidepressants in Bipolar Disorder?</itunes:title>
      <itunes:author>Joseph Goldberg MD, Greg Mattingly MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/3ebf6bac-44e1-4c51-b67d-1081dbf65e99/8e49ee44-c32e-44a8-8e82-52e8eeeeb68f/3000x3000/sy-bipolar-depression-podcasticon-antidepressants.jpg?aid=rss_feed"/>
      <itunes:duration>00:34:47</itunes:duration>
      <itunes:summary>Joseph Goldberg, MD, and Greg Mattingly, MD, discuss the role of antidepressants in bipolar disorder. </itunes:summary>
      <itunes:subtitle>Joseph Goldberg, MD, and Greg Mattingly, MD, discuss the role of antidepressants in bipolar disorder. </itunes:subtitle>
      <itunes:keywords>psychotherapies, bipolar ii, bipolar disorder, depression, bipolar i, psychiatric, psychiatry, neuroscience, mania, bipolar depression, mood disorders, mdd</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>6</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">adf42475-dd45-4e50-a8de-dc897a2822fd</guid>
      <title>Diagnostic Dilemmas in Differentiating Unipolar and Bipolar Depression</title>
      <description><![CDATA[<p>In this episode, Leslie Citrome, MD, MPH, and Manpreet K. Singh, MD, MS, discuss diagnosing unipolar vs bipolar depression. They review why it can be difficult to differentiate between unipolar and bipolar depression; which screening tools they employ, including the rapid mood screener (RMS); how to reduce chances of missing mania; and special tips for differentiating between major depressive disorder (MDD) and bipolar depression in children.  </p><p>Presenters:</p><p><strong>Leslie Citrome, MD, MPH</strong><br /><i>Clinical Professor</i><br />Department of Psychiatry and Behavioral Sciences<br />New York Medical College<br />Valhalla, New York</p><p><strong>Manpreet K. Singh, MD, MS</strong><br /><i>Associate Professor of Psychiatry and Behavioral Sciences</i><br />Stanford University<br />Stanford, California</p><p>Link to full program:<br /><a href="https://bit.ly/3syJzh2" target="_blank">https://bit.ly/3syJzh2</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Fri, 20 Aug 2021 20:35:00 +0000</pubDate>
      <author>support@deceraclinical.com (Manpreet K Singh MD MS, Leslie Citrome MD MPH)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/diagnostic-dilemmas-in-differentiating-unipolar-and-bipolar-depression-2MnmZgsX</link>
      <content:encoded><![CDATA[<p>In this episode, Leslie Citrome, MD, MPH, and Manpreet K. Singh, MD, MS, discuss diagnosing unipolar vs bipolar depression. They review why it can be difficult to differentiate between unipolar and bipolar depression; which screening tools they employ, including the rapid mood screener (RMS); how to reduce chances of missing mania; and special tips for differentiating between major depressive disorder (MDD) and bipolar depression in children.  </p><p>Presenters:</p><p><strong>Leslie Citrome, MD, MPH</strong><br /><i>Clinical Professor</i><br />Department of Psychiatry and Behavioral Sciences<br />New York Medical College<br />Valhalla, New York</p><p><strong>Manpreet K. Singh, MD, MS</strong><br /><i>Associate Professor of Psychiatry and Behavioral Sciences</i><br />Stanford University<br />Stanford, California</p><p>Link to full program:<br /><a href="https://bit.ly/3syJzh2" target="_blank">https://bit.ly/3syJzh2</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="30295006" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/d3cde6f8-dd44-4a01-9e82-e961558b1262/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=d3cde6f8-dd44-4a01-9e82-e961558b1262&amp;feed=K2gejSy4"/>
      <itunes:title>Diagnostic Dilemmas in Differentiating Unipolar and Bipolar Depression</itunes:title>
      <itunes:author>Manpreet K Singh MD MS, Leslie Citrome MD MPH</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/3ebf6bac-44e1-4c51-b67d-1081dbf65e99/342c2bec-41f5-4c38-be18-068229c0507b/3000x3000/sy-bipolar-depression-podcasticon-1.jpg?aid=rss_feed"/>
      <itunes:duration>00:31:31</itunes:duration>
      <itunes:summary>Leslie Citrome, MD, MPH, and Manpreet K. Singh, MD, MS, discuss diagnostic dilemmas in differentiating unipolar and bipolar depression. </itunes:summary>
      <itunes:subtitle>Leslie Citrome, MD, MPH, and Manpreet K. Singh, MD, MS, discuss diagnostic dilemmas in differentiating unipolar and bipolar depression. </itunes:subtitle>
      <itunes:keywords>rapid mood screener, psychotherapies, bipolar disorder, depression, unipolar depression, psychiatric, psychiatry, neuroscience, mania, bipolar depression, rms, mood disorders, mdd</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>5</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">db300f80-863a-4aec-98ce-7b12fb74ad1e</guid>
      <title>Dilemmas in TD in Primary Care</title>
      <description><![CDATA[<p>In this episode, Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh , discuss how the use of antipsychotics has changed in primary care patients, how primary care physicians can screen for tardive dyskinesia (TD), and increasing needs for the primary care physician in mental health.</p><p>Presenters:</p><p><strong>Greg Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry, Psychopharmacology<br />Washington University School of Medicine<br />St Louis, Missouri<br />President<br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p><strong>W. Clay Jackson, MD, DipTh</strong>  <br /><i>Assistant Professor of Clinical Family Medicine & Psychiatry</i><br />College of Medicine<br />University of Tennessee<br /><i>Director</i><br />Palliative Care<br />West Cancer Center<br />Memphis, Tennessee</p><p>Link to full program:<br /><a href="https://bit.ly/2RM8hfM" target="_blank">https://bit.ly/2RM8hfM</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Fri, 20 Aug 2021 20:30:00 +0000</pubDate>
      <author>support@deceraclinical.com (W Clay Jackson MD DipTh, Greg Mattingly MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/dilemmas-in-td-in-primary-care-pVcVPSiN</link>
      <content:encoded><![CDATA[<p>In this episode, Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh , discuss how the use of antipsychotics has changed in primary care patients, how primary care physicians can screen for tardive dyskinesia (TD), and increasing needs for the primary care physician in mental health.</p><p>Presenters:</p><p><strong>Greg Mattingly, MD</strong><br /><i>Associate Clinical Professor</i><br />Psychiatry, Psychopharmacology<br />Washington University School of Medicine<br />St Louis, Missouri<br />President<br />St Charles Psychiatry Associates<br />St Charles, Missouri</p><p><strong>W. Clay Jackson, MD, DipTh</strong>  <br /><i>Assistant Professor of Clinical Family Medicine & Psychiatry</i><br />College of Medicine<br />University of Tennessee<br /><i>Director</i><br />Palliative Care<br />West Cancer Center<br />Memphis, Tennessee</p><p>Link to full program:<br /><a href="https://bit.ly/2RM8hfM" target="_blank">https://bit.ly/2RM8hfM</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="30005121" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/7c301c6c-1cf1-470d-8308-28b647156ad2/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=7c301c6c-1cf1-470d-8308-28b647156ad2&amp;feed=K2gejSy4"/>
      <itunes:title>Dilemmas in TD in Primary Care</itunes:title>
      <itunes:author>W Clay Jackson MD DipTh, Greg Mattingly MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/3ebf6bac-44e1-4c51-b67d-1081dbf65e99/b73d0fcc-62ea-45b8-875e-cbb3cf0e9b1d/3000x3000/sy-tardive-dyskinesia-podcasticon-4.jpg?aid=rss_feed"/>
      <itunes:duration>00:31:13</itunes:duration>
      <itunes:summary>Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh, discuss dilemmas in tardive dyskinesia (TD) in primary care. </itunes:summary>
      <itunes:subtitle>Greg Mattingly, MD, and W. Clay Jackson, MD, DipTh, discuss dilemmas in tardive dyskinesia (TD) in primary care. </itunes:subtitle>
      <itunes:keywords>tardive dyskinesia, psychotherapies, telepsychiatry, psychiatric, dyskinesia, aims exam, primary care, telepsych, antipsychotics</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>4</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">1e8a3494-a718-4509-9860-c5d8a73c093f</guid>
      <title>Relationship of EPS, Antiparkinsonian Drugs, and TD</title>
      <description><![CDATA[<p>In this episode, John M. Kane, MD, and Rebecca S. Roma, MD, discuss clinical assessment of extrapyramidal symptoms (EPS), antiparkinsonian drugs, and tardive dyskinesia (TD). They review differentiating between TD and EPS, identify tools for diagnosing TD, and provide some important clinical pearls and evidence-based reasons for choosing different medications for treating EPS and TD.</p><p>Presenters:</p><p><strong>John M. Kane, MD</strong><br /><i>Professor and Chairman</i><br />Department of Psychiatry<br />Donald and Barbara Zucker School of Medicine at Hofstra/Northwell<br />Glen Oaks, New York</p><p><strong>Rebecca S. Roma, MD</strong><br /><i>Medical Director</i><br />REACH, LLC<br />Pittsburgh, Pennsylvania</p><p>Link to full program:<br /><a href="https://bit.ly/2RM8hfM" target="_blank">https://bit.ly/2RM8hfM</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Tue, 20 Jul 2021 20:30:00 +0000</pubDate>
      <author>support@deceraclinical.com (John M Kane MD, Rebecca S Roma MD)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/relationship-of-eps-antiparkinsonian-drugs-and-td-xGBRILLV</link>
      <content:encoded><![CDATA[<p>In this episode, John M. Kane, MD, and Rebecca S. Roma, MD, discuss clinical assessment of extrapyramidal symptoms (EPS), antiparkinsonian drugs, and tardive dyskinesia (TD). They review differentiating between TD and EPS, identify tools for diagnosing TD, and provide some important clinical pearls and evidence-based reasons for choosing different medications for treating EPS and TD.</p><p>Presenters:</p><p><strong>John M. Kane, MD</strong><br /><i>Professor and Chairman</i><br />Department of Psychiatry<br />Donald and Barbara Zucker School of Medicine at Hofstra/Northwell<br />Glen Oaks, New York</p><p><strong>Rebecca S. Roma, MD</strong><br /><i>Medical Director</i><br />REACH, LLC<br />Pittsburgh, Pennsylvania</p><p>Link to full program:<br /><a href="https://bit.ly/2RM8hfM" target="_blank">https://bit.ly/2RM8hfM</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="29677794" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/dabab3d2-d397-4acc-aa38-ac7a3b81f8f8/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=dabab3d2-d397-4acc-aa38-ac7a3b81f8f8&amp;feed=K2gejSy4"/>
      <itunes:title>Relationship of EPS, Antiparkinsonian Drugs, and TD</itunes:title>
      <itunes:author>John M Kane MD, Rebecca S Roma MD</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/86952976-b928-4317-884c-2c7ba3b2ae4d/1b4a1bbd-b3eb-4fa9-b9c0-fe4585324e98/3000x3000/sy-tardive-dyskinesia-podcasticon-eps.jpg?aid=rss_feed"/>
      <itunes:duration>00:30:52</itunes:duration>
      <itunes:summary>John M. Kane, MD, and Rebecca S. Roma, MD, discuss the relationship of extrapyramidal symptoms, antiparkinsonian drugs, and tardive dyskinesia.</itunes:summary>
      <itunes:subtitle>John M. Kane, MD, and Rebecca S. Roma, MD, discuss the relationship of extrapyramidal symptoms, antiparkinsonian drugs, and tardive dyskinesia.</itunes:subtitle>
      <itunes:keywords>tardive dyskinesia, schizophrenia, psychotherapies, telepsychiatry, psychiatric, psychiatry, dyskinesia, aims exam, neurology, movement disorders, telepsych, antipsychotics</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>3</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">bb1b65d2-f6d9-4363-a880-0029c79e8fd6</guid>
      <title>Diagnosing TD in Clinical Practice</title>
      <description><![CDATA[<p>In this episode, Leslie Citrome, MD, MPH, and Joseph P. McEvoy, MD, discuss clinical assessment and diagnosis of tardive dyskinesia (TD). They review using the AIMS exam for identification of dyskinesia in patients in both the clinical setting and via telepsychiatry. They also review how often to perform the AIMS exam, how to assess the results, and why it is important.</p><p>Presenters:<br /><strong>Leslie Citrome, MD, MPH</strong><br /><i>Clinical Professor</i><br />Department of Psychiatry and Behavioral Sciences<br />New York Medical College<br />Valhalla, New York</p><p><strong>Joseph P. McEvoy, MD</strong><br /><i>Professor</i><br />Psychiatry and Health Behavior<br /><i>Psychiatrist</i><br />Augusta University<br />Augusta, Georgia</p><p>Link to full program:<br /><a href="https://bit.ly/2RM8hfM" target="_blank">https://bit.ly/2RM8hfM</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Fri, 11 Jun 2021 23:00:00 +0000</pubDate>
      <author>support@deceraclinical.com (Joseph P. McEvoy MD, Leslie Citrome MD MPH)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/clinical-diagnosis-of-td-zWkghdbo</link>
      <content:encoded><![CDATA[<p>In this episode, Leslie Citrome, MD, MPH, and Joseph P. McEvoy, MD, discuss clinical assessment and diagnosis of tardive dyskinesia (TD). They review using the AIMS exam for identification of dyskinesia in patients in both the clinical setting and via telepsychiatry. They also review how often to perform the AIMS exam, how to assess the results, and why it is important.</p><p>Presenters:<br /><strong>Leslie Citrome, MD, MPH</strong><br /><i>Clinical Professor</i><br />Department of Psychiatry and Behavioral Sciences<br />New York Medical College<br />Valhalla, New York</p><p><strong>Joseph P. McEvoy, MD</strong><br /><i>Professor</i><br />Psychiatry and Health Behavior<br /><i>Psychiatrist</i><br />Augusta University<br />Augusta, Georgia</p><p>Link to full program:<br /><a href="https://bit.ly/2RM8hfM" target="_blank">https://bit.ly/2RM8hfM</a></p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="27339065" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/0ccf9914-338e-4933-92fe-e4bdcd247f33/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=0ccf9914-338e-4933-92fe-e4bdcd247f33&amp;feed=K2gejSy4"/>
      <itunes:title>Diagnosing TD in Clinical Practice</itunes:title>
      <itunes:author>Joseph P. McEvoy MD, Leslie Citrome MD MPH</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/165defb8-f7d7-44fe-a7eb-a59f2c35d334/861c524c-52aa-49c1-95f8-116c963d8c15/3000x3000/sy-tardive-dyskinesia-diagnosis-podcasticon.jpg?aid=rss_feed"/>
      <itunes:duration>00:28:27</itunes:duration>
      <itunes:summary>Leslie Citrome, MD, MPH, and Joseph P. McEvoy, MD, discuss diagnosis of tardive dyskinesia (TD) in clinical practice.</itunes:summary>
      <itunes:subtitle>Leslie Citrome, MD, MPH, and Joseph P. McEvoy, MD, discuss diagnosis of tardive dyskinesia (TD) in clinical practice.</itunes:subtitle>
      <itunes:keywords>tardive dyskinesia, telepsychiatry, psychiatric, dyskinesia, aims exam, telepsych, antipsychotics</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>2</itunes:episode>
    </item>
    <item>
      <guid isPermaLink="false">f200f43a-350b-45f8-9199-b04ea9c1cc79</guid>
      <title>Mood Disorders, Antipsychotics, and TD</title>
      <description><![CDATA[<p>In this episode, Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss tardive dyskinesia (TD), mood disorders, and antipsychotics. They review current clinical considerations and assessments, including whether antipsychotic prescriptions for mood disorders have increased, if patients with mood disorder are at higher risk for TD and why, and when and how to use an AIMS exam, even in telepsychiatry. They also review the evidence base for VMAT2 inhibitors in TD, what nonevidence-based treatments healthcare professionals should avoid, and how to choose between the 2 VMAT2 inhibitors.  </p><p>Presenters:</p><p><strong>Roger McIntyre, MD, FRCPC</strong><br /><i>Professor of Psychiatry and Pharmacology</i><br />Department of Psychiatry/Pharmacology<br />University of Toronto<br /><i>Head</i>, Mood Disorders Psychopharmacology Unit<br />Department of Psychiatry<br />Toronto, Canada</p><p><strong>Joseph Goldberg, MD</strong><br /><i>Clinical Professor of Psychiatry</i><br />Department of Psychiatry<br />Icahn School of Medicine at Mount Sinai<br />New York, New York</p><p>Content based on an online CME program supported by an educational grant from Neurocrine Biosciences.</p><p>Link to full program:<br /><a href="https://bit.ly/2RM8hfM">https://bit.ly/2RM8hfM</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></description>
      <pubDate>Mon, 24 May 2021 20:30:00 +0000</pubDate>
      <author>support@deceraclinical.com (Joseph Goldberg MD, Roger McIntyre MD FRCPC)</author>
      <link>https://neurologypodcast.simplecast.com/episodes/mood-disorders-antipsychotics-and-td-lu1zFLHR</link>
      <content:encoded><![CDATA[<p>In this episode, Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss tardive dyskinesia (TD), mood disorders, and antipsychotics. They review current clinical considerations and assessments, including whether antipsychotic prescriptions for mood disorders have increased, if patients with mood disorder are at higher risk for TD and why, and when and how to use an AIMS exam, even in telepsychiatry. They also review the evidence base for VMAT2 inhibitors in TD, what nonevidence-based treatments healthcare professionals should avoid, and how to choose between the 2 VMAT2 inhibitors.  </p><p>Presenters:</p><p><strong>Roger McIntyre, MD, FRCPC</strong><br /><i>Professor of Psychiatry and Pharmacology</i><br />Department of Psychiatry/Pharmacology<br />University of Toronto<br /><i>Head</i>, Mood Disorders Psychopharmacology Unit<br />Department of Psychiatry<br />Toronto, Canada</p><p><strong>Joseph Goldberg, MD</strong><br /><i>Clinical Professor of Psychiatry</i><br />Department of Psychiatry<br />Icahn School of Medicine at Mount Sinai<br />New York, New York</p><p>Content based on an online CME program supported by an educational grant from Neurocrine Biosciences.</p><p>Link to full program:<br /><a href="https://bit.ly/2RM8hfM">https://bit.ly/2RM8hfM</a></p><p> </p><br/> <p>Hosted by Simplecast, an AdsWizz company. See <a href="https://pcm.adswizz.com">pcm.adswizz.com</a> for information about our collection and use of personal data for advertising.</p>]]></content:encoded>
      <enclosure length="34375884" type="audio/mpeg" url="https://afp-928689-injected.calisto.simplecastaudio.com/30492008-11c5-48d3-9f46-e962c551c196/episodes/d50ab265-4913-49cc-98d0-856b688cfb37/audio/128/default.mp3?aid=rss_feed&amp;awCollectionId=30492008-11c5-48d3-9f46-e962c551c196&amp;awEpisodeId=d50ab265-4913-49cc-98d0-856b688cfb37&amp;feed=K2gejSy4"/>
      <itunes:title>Mood Disorders, Antipsychotics, and TD</itunes:title>
      <itunes:author>Joseph Goldberg MD, Roger McIntyre MD FRCPC</itunes:author>
      <itunes:image href="https://image.simplecastcdn.com/images/3ebf6bac-44e1-4c51-b67d-1081dbf65e99/ae926e74-7296-4370-93a3-35542340cc9a/3000x3000/sy-tardive-dyskinesia-podcasticon.jpg?aid=rss_feed"/>
      <itunes:duration>00:35:46</itunes:duration>
      <itunes:summary>Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss mood disorders, antipsychotics and tardive dyskinesia (TD). </itunes:summary>
      <itunes:subtitle>Roger McIntyre, MD, FRCPC, and Joseph Goldberg, MD, discuss mood disorders, antipsychotics and tardive dyskinesia (TD). </itunes:subtitle>
      <itunes:keywords>bipolar disorders, tardive dyskinesia, depression, telepsychiatry, psychiatric, dyskinesia, aims exam, telepsych, mood disorders, antipsychotics</itunes:keywords>
      <itunes:explicit>false</itunes:explicit>
      <itunes:episodeType>full</itunes:episodeType>
      <itunes:episode>1</itunes:episode>
    </item>
  </channel>
</rss>